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Background: The pathogenesis of IgA Nephropathy (IgAN) is poorly understood 
globally and curative therapy currently does not exist.  Variable presentation 
among IgAN patients globally may be indicative of various underlying 
pathogenic mechanisms.  Pathogenetic data on IgAN in Africa is scarce to nil.  
The current study provides the first O-glycosylation data for IgAN in South 
Africa or Africa. 
 
Methods: An enzyme-linked immunosorbent assay-type lectin binding assay was 
used to compare the serum IgA1 O-galactosylation in 19 IgAN patients and 20 
controls.  During 2007, 2009, and 2011, blood was extracted from consenting 
biopsy-diagnosed South African IgAN patients of African, Caucasian, Indian 
(predominantly) and mixed-race descent in KwaZulu Natal.  The mean 
absorbance value corresponding to the degree of degalactosylation for the IgAN 
group was compared to that of the normal control group for each test.  A non-
parametric Wilcoxon matched-pairs test was used accordingly.  The two-tailed p-
value was used to assess for statistical significance between the groups.  The low 
number of attending and consenting IgAN patients precluded IgA1 O-
galactosylation analyses between race, gender, and disease stage.  
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Results: The average means of the experiments for the IgAN group is 0.3678 ± 
0.0790 (SEM) and is statistically significantly greater than the normal control 
group which is 0.2969 ± 0.0586 (SEM); (p = 0.0076).   
 
Conclusion: Thus, IgAN patients exhibited abnormal IgA1 O-glycosylation with 
a greater level of terminal degalactosylation of IgA1 in comparison to controls. 
Such a finding is consistent with other studies in Caucasian and Asian 
populations globally.  Future specific therapeutic strategies that target the 
formation of abnormal glycosylation in IgA1 may be potentially beneficial in the 
study population.     
 
CHAPTER 1 - INTRODUCTION 
 
1.1 Definition of IgAN 
 
IgAN, also eponymously known as Berger’s disease, was first described in 1968 
by Berger and Hinglais, as the presence of mesangial deposits of 
immunoglobulin A (IgA) and lesser amounts of complement (C) 3, as detected 
by immunofluorescence in patients with frequent episodes of asymptomatic 
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haematuria and proteinuria.  Berger subsequently proposed primary 
glomerulonephritis, with a predominance of mesangial IgA deposits, as being a 
distinct disease entity (1969).   
 
1.2 Role and Structure of IgA 
 
IgA is the most abundant antibody in mucosal secretions, and plays a significant 
role as the first line of defence against invading pathogenic organisms and the 
entry of commensals at the mucosal border (Kerr, 1990).  IgA is also present in 
the serum where it is the second most common antibody and serves as the second 
line of defence.   
 
Two subclasses of IgA exist, i.e. IgA1 and IgA2.  Monomeric IgA1 consists of 
two identical heavy and two identical light polypeptide chains (Kerr, 1990).  The 
heavy and light chains are held together by disulphide bonds and non-covalent 
interactions.  Dimeric IgA1 consists of two IgA monomers covalently linked by 
a polypeptide J chain (fig. 1).  The cysteine (Cys) 471 in one tailpiece of each Fc 
fragment is disulphide-bridged with either Cys 14 or Cys 68 of the J chain.    
Each heavy chain consists of a variable domain, referred to as the variable heavy 
domain (VH), and 3 constant heavy (CH) domains.  Each light chain consists of 
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1 variable light (VL) and 1 constant light domain (CL) domain.  The constant 
domain contains an amino acid sequence that does not vary between 
immunoglobulins of a particular class; whilst the variable region differs between 
immunoglobulins produced by different B-lymphocytes.  The variable regions 
form the antigen binding sites.  The region within the antibody that complements 
the shape of the antigen is referred to as the complementarity determining region 
(CDR). 
 
The proteolytic enzyme, papain, cleaves the hinge region to yield two fragments 
of antigen binding or Fab fragments and 1 fragment of crystallisation or Fc 
fragment, per monomer.  Each Fab fragment contains the VH and CH1 domains, 






Figure 1:  Schematic Representation of the Dimeric IgA1 Molecule (Bonner 
et al, 2008) - reproduced following permission from the Journal of Immunology - 
Copyright 2008.  The American Association of Immunologists, Inc. (Appendix 9) 
 
The hinge region confers flexibility to the antibody molecule and contains the O-
glycosylation sites.  Unlike IgA1, the IgA2 hinge region does not contain O-
glycosylation sites and is shorter (Furtado et al, 2004).  The deposited mesangial 
IgA in IgAN is polymeric IgA1.  This difference prompted investigation into the 
pathogenic role of abnormal IgA1 O-glycosylation.   
Key: 
 
○ - O-linked 
Oligosaccharides 
 











1.3 Rationale for the Analysis of IgA1 O-Galactosylation, in    
      a South African population of IgAN patients 
 
1.3.1 The Regulatory and Excretory Roles of the Kidney are   
         affected in IgAN 
 
The kidneys are responsible for the regulation of the acid-base balance; water 
and electrolyte balances; body fluid osmolarity and electrolyte concentrations; 
and arterial pressure.  The kidneys excrete metabolic waste products, toxins and 
foreign chemicals; secrete hormones (e.g. erythropoietin); and are involved in 
gluconeogenesis (Guyton & Hall, 1997).  
 
The nephron is the functional unit of the kidney.  Each kidney at birth contains 
approximately one million nephrons.  The nephron contains the initial filtering 
component (the renal corpuscle) and a tubule specialised for reabsorption and 
secretion (the renal tubule).  The renal corpuscle consists of the glomerulus and 
the Bowman’s capsule.  The glomerulus is situated within the Bowman’s capsule 




The glomerulus is a tuft of capillaries that performs the initial homeostatic 
filtration step in the formation of urine.  IgAN is a primary glomerular disease 
that is diffuse (i.e. affecting all, or at least 50% of the glomeruli) and global (i.e. 
affecting the whole glomerulus, usually uniformly; or more than 50% of the 
glomerular segments) (Lawler, 1991).  The kidney cannot regenerate new 
nephrons and the homeostatic functions are thus disrupted during the disease 
(Guyton & Hall, 1997). 
 
1.3.2 Diagnosis and Clinical Manifestation of IgAN 
  
The diagnosis of IgAN is made by the immunofluorescence staining of renal 
biopsy material.  In IgAN, generalised, diffuse IgA1 deposition in the mesangia 
of all glomeruli, as the predominant immunoglobulin or co-dominant 
immunoglobulin with IgM, IgG, or both, is detected (Anderton & Thomson, 
1988).   
 
In patients with a moderate or advanced stage of IgAN, increased 
immunofluorescence staining of extra-cellular matrix components, such as type 
IV collagen, laminin and fibronectin, in the glomerular capillary walls and or 
26 
 
mesangia, has also been reported.  In addition, C3, C5b-9, properdin and 
fibrinogen are usually detected.  C1q may be present in minimal amounts.   
 
In the absence of disease, the filterability of the solute is dependent on the size 
and charge of the molecule.  Negatively charged, large molecules are filtered less 
easily than positively charged molecules of equal size.  Negatively charged 
albumin, the most abundant serum protein, is repelled by the negative charges of 
the basement membrane proteoglycans, and is thus restricted from filtration.  As 
the molecular weight of a molecule approaches that of albumin, the filterability 
rapidly decreases, approaching zero (Guyton & Hall, 1997).  In IgAN, however, 
insoluble immune complexes become entrapped in the glomeruli, especially in 
the basement membrane.  The entrapment of insoluble immune complexes 
results in the proliferation of many glomerular cells, mainly the epithelial and 
mesangial cells that lie between the endothelium and epithelium.  In addition, the 
inflammatory reaction results in the entrapment of large numbers of leukocytes, 
causing blockage of many glomeruli.  Unblocked glomeruli become excessively 
permeable, allowing both protein and erythrocytes to leave the blood of the 




Clinical features of IgAN include gross haematuria that may follow respiratory 
infection; malaise; loin discomfort; and low-grade fever.  A common finding is 
microscopic haematuria, with or without proteinuria, upon urinalysis (Anderton 
& Thomson, 1988). 
 
The glomerular leakage of proteins and cytokines result in the injury and 
activation of the tubular epithelium.  This in turn triggers the infiltration of 
leukocytes and the associated fibrotic response. 
 
The ultrafiltered protein load of tubular epithelial cells activates mechanisms of 
tubulointerstitial injury and accelerates the progression of disease to end-stage 
renal failure (Abbate et al, 2006).  The load of plasma proteins stimulates the 
expression of proinflammatory and profibrotic mediators in renal tubular cells 
(Tang et al, 2003; Drumm et al, 2002; Yard et al, 2001; Wang et al, 1997).   
 
Zoja et al demonstrated in vitro that the plasma protein load induces the 
synthesis of vasoconstrictor peptide endothelin-1 in proximal tubular cells and 
mediates progressive renal injury by stimulating renal cell proliferation, 
extracellular matrix production and the attraction of monocytes (1995). 
Macrophages which feature prominently in the interstitial inflammatory 
28 
 
infiltrate, mediates the progression of renal injury, and macrophage numbers in 
renal biopsy may predict renal survival in chronic renal disease (Eardley et al, 
2006).  Macrophages regulate matrix accumulation via the release of growth 
factors such as transforming growth factor ß (TGF-ß) (Abbate et al, 2002).  
TGF-ß stimulates the transformation of interstitial cells into myofibroblasts.  
Proximal tubular epithelial cells promote fibrogenesis via the paracrine release of 
TGF-ß. 
 
Donadelli et al demonstrated in vitro the induction of fractalkine in proximal 
tubular cells via protein overload (2003).  Fractalkine may contribute to directing 
mononuclear cells into the peritubular interstitium and enhancing their adhesion 
property, thus favouring interstitial inflammation and disease progression.   
 
Tang et al, demonstrated in vivo and in vitro the role of albumin in the 
upregulation of the potent chemokine interleukin (IL) 8 in proximal tubular 
epithelial cells through nuclear factor kappa-light-chain-enhancer of activated B- 
cells (NF-Κb)-dependent pathways (2003).  Acute exposure to albumin induced 
interleukin 8 expression in a time and dose-dependent manner.  The generation 




Excess complement ultrafiltration and complement synthesis in proximal tubular 
cells may underlie complement-mediated injury in chronic proteinuric renal 
disease.  Tang et al demonstrated the upregulation of C3 messenger ribonucleic 
acid (mRNA) and biosynthesis in proximal tubular epithelial cells due to protein 
overload at the apical surface (1999). 
 
Erkan et al demonstrated a dose and duration-dependent induction of apoptosis 
of cultured proximal tubular cells following albumin overload; mediated at least 
in part by the Fas-associated death domain protein-caspase 8 pathway (2001).   
 
The deposition of C3 in the mesangium may be found in association with 
  
tissue 
injury in IgAN.  While IgA does not fix complement, it may activate the 
complement cascade of the alternative pathway (Hiemstra et al, 1987).  
Activated complement may cause tissue injury either directly or indirectly by 
recruiting effector cells, which in turn may promote local inflammation when 
activated (Couser, 1985).   
 
Renal IgA deposition is also noted in other disorders, viz. Henoch-Schönlein 
purpura (HSP), systemic lupus erythematosus and liver disease (Sinniah & Feng, 
1976; Callard et al, 1975; Urizar et al, 1968). 
30 
 
1.3.3 Prognosis in IgAN 
 
Raised serum creatinine concentrations, and proteinuria at presentation, are 
predictive of a poor prognosis.  Male gender, late age at onset, and persistent 
microscopic haematuria, are also predictors of disease progression.  
Hypertension is a significant prognostic factor for progression in those patients 
with normal renal function (Ibels & Gyory, 1994).   
 
Tubulointerstitial, vascular and glomerular lesions are histological markers of 
disease progression (Daniel et al, 2000; Mera et al, 2000; To et al, 2000; 
Bogenschutz et al, 1990).  Walsh et al have demonstrated that interstitial 
fibrosis, glomerular sclerosis, and crescent formation, independently predicted 
adverse outcomes defined as a composite of doubling of serum creatinine levels, 
end-stage renal disease (ESRD), or death (2010).   
 
Capillary wall IgA deposition rather than purely mesangial deposition is also 
indicative of more aggressive disease (Yoshimura et al, 1987).  An increased 
level of circulatory fibroblast growth factor-23, a regulator of phosphorous 
homeostasis, was associated with albuminuria and disease progression in chronic 
IgAN (Lundberg et al, 2012).  
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1.3.4 Incidence and Prevalence of IgAN 
 
Since the diagnosis of IgAN is made by renal biopsy, incidence data is 
dependent on the practice of biopsy.  However, policies governing biopsy-
practice varies globally.  In addition, many cases of IgAN remain undiagnosed 
even in regions where biopsy is practiced.  Nephrologists may be reluctant to 
perform biopsies on asymptomatic patients with mild abnormalities upon 
urinalysis; and lack of access to health care prevents biopsy and diagnosis in 
certain individuals.  Conditions such as shrunken kidneys, for example, may 
preclude biopsy.  Thus, the true incidence of IgAN cannot be determined for a 
population.   
 
IgAN is the most common type of primary glomerulonephritis in regions where 
biopsy is conducted.  From a review of 40 studies on the incidence of primary 
glomerulonephritis in Europe, North and South America, Canada, Australasia 
and the Middle East, the incidence rate for IgAN was the highest (McGrogan et 
al, 2011).  In the unit of per 100 000 per year, the incidence for IgAN was 2.5; 
compared to 1.2 for membranous nephropathy, 0.2 for membrano-proliferative 
glomerulonephritis, 0.8 for focal segmental glomerulosclerosis, 0.6 for minimal 
change disease, and 0.2 for mesangio-proliferative glomerulonephritis.  
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Systematic study for IgAN incidence data in Africa is hampered by restriction of 
renal biopsy due to cost (Seedat, 1992).  In 1992, Oviasu reported IgAN in a 
Nigerian male and suggested that the rarity of IgAN in African Blacks may be 
unlikely.  In 1997, a similar incidence for Caucasian and African-American 
children and adolescents has been reported (Sehic et al, 1997). 
 
Although all racial groups are affected by IgAN, the highest prevalence has been 
reported in certain groups of Asian and European descent (Julian et al, 1988).  
Prevalence rates of up to 40% in Asia, 20% in Europe and 10% in North 
America, were reported among all biopsies carried out for glomerular diseases.  
In Asia, the reported prevalence is comparatively higher as routine urinalyses are 
performed for schoolchildren and renal biopsies are performed on patients with 
asymptomatic haematuria.  In Singapore, the mandatory screening practice for 
urinary abnormalities in army recruits has also resulted in the reporting of a high 
incidence of IgAN in Singaporean Asian males (Sinniah et al, 1976).  Reported 
incidences may thus reflect policies governing biopsy practice, which may vary 
in different countries.    
 
However, a geospatial analysis of 85 populations revealed that the genetic risk 
score based on the replicated genome-wide association studies (GWAS) loci was 
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highest in Asians; intermediate in Europeans; and the least in Africans.  Such 
data reflect current incidence data for IgAN (Kiryluk et al, 2013). 
 
1.3.5 Serology in IgAN 
 
The sera of patients with  IgAN may be characterised by increased levels of 
circulating IgA1-containing immune complexes; high levels of polymeric IgA1 
in more than 50% of the patients (Tomana et al, 1999; Schena et al, 1989; Lai et 
al, 1987; Czerkinsky et al, 1986; Valentijn et al, 1984; Coppo et al, 1982); and 
an increased number of IgA1-bearing B-lymphocytes (Schena et al, 1986) and 
activated T helper cells (Lai et al, 1994).  In vitro studies have demonstrated 
overproduction of IgA1 by B-lymphocytes from the sera of patients with IgAN 
(Schena et al, 1986; Sakai et al, 1979).  An increased concentration of C3 may 










1.3.6 Primary Pathogenic Defect in IgAN 
 
1.3.6.1 The Primary Pathogenic Defect/s Are External to the Kidney 
 
Donor kidneys from patients with sub-clinical IgAN that were transplanted in 
patients without IgAN became clear of immune deposits over several weeks 
(Sanfilippo et al, 1982; Silva et al, 1982).  In addition, histological recurrence of 
mesangial IgA1 deposition may be seen beyond three months post-
transplantation in patients with IgAN (Odum et al, 1994).  Thus, the primary 
pathogenic defect does not lie within the kidney.    
 
 In a retrospective study of 190 IgAN patients and 380 non-diabetic controls, at 
15 years, IgAN patients had a higher cumulative incidence of graft failures 
(Moroni et al, 2013).  At multivariate analysis, IgAN, delayed graft function and 








1.3.6.2 Abnormalities of Production Control Do not Provide a Direct   
            Explanation for Mesangial Deposition 
 
IgAN does not occur in other diseases with raised serum IgA1 levels viz. IgA 
myeloma, unless the IgA1 molecules are aberrantly glycosylated (Tanaka et al, 
2011; Feehally & Allen, 1999).  Hence, abnormalities of control of IgA1 
production do not provide a direct explanation for mesangial deposition of IgA1. 
 
1.3.6.3 Role of the O-Galactosylation of the IgA1 Glycoprotein 
 
The carbohydrate moiety of the glycoprotein aids in the maintenance of the 
biologically active conformation and structural stability; decreases 
immunogenicity; confers protection against proteolysis; and serves as ligands for 
cell receptors.  Immunoglobulins are glycoproteins.  The O-linked carbohydrate 
moieties of the IgA1 hinge region (fig. 2) constitute the recognition motif of the 
asialoglycoprotein receptor (ASGPR) of the liver (Stockett et al, 1982).  
Terminal O-linked D-galactose (fig. 2) is the ligand of the hepatic ASGPR, and  
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Figure 2: Schematic Representation of the O-Galactosylation Sites and O-
Galactosylation at the Hinge Region between the CH1 and CH2 domains of 
IgA1 
 
1.3.6.4 Hypogalactosylation of the IgA1 Glycoprotein in IgAN 
 
Several of the pioneering studies on the O-galactosylation of IgA1 have 
demonstrated that the serum IgA1 is aberrantly glycosylated (Allen et al, 2001; 
Amore et al, 2001; Allen & Feehally, 2000; Allen et al, 1999; Hiki et al, 1998; 
Tomana et al, 1997; Hiki et al, 1996; Allen et al, 1995; Tomana et al, 1995; 
Key: 
 
CH - Constant heavy domain of IgA1 
Pro - Proline 
Ser - Serine 
Thr - Threonine 
GalNAc - N-Acetylgalactosamine 
Gal - Galactose 
NeuNAc - N-Acetylneuraminic acid  
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Mestecky et al, 1993).  These studies were conducted primarily in Caucasian or 
Asian populations. 
 
1.3.6.5 Hypogalactosylation of IgA1 and the Resultant Generation of   
            Circulating Immune Complexes 
 
Incomplete O-galactosylation results in the exposure of neo-antigenic N-
Acetylgalactosamine (GalNAc).  Neo-antigenic GalNAc may be recognised by 
GalNAc-specific IgG or IgA1, resulting in the increased level of circulatory 
immune complexes
 
(Mestecky et al, 2002; Tomana et al, 1999; Tomana et al, 
1997; Schena et al, 1989; Coppo et al, 1982).  Hashimoto et al used two IgAN 
mouse models to study the pathological role of complement pathways in IgAN 
(2012).  The mouse model with the significantly greater level of IgA 
hypogalactosylation correlated with a significantly greater level of circulating 
immune complexes despite having significantly lesser levels of serum IgA than 
the latter.   
 
Since terminal D-galactose is the ligand of the hepatic asialoglycoprotein 
receptor, galactose-deficient IgA1 molecules and galactose-deficient IgA1-
containing immune complexes, in the sera of patients with IgAN, may thus 
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escape hepatic clearance, the major catabolic pathway of IgA1, and persist in the 
circulation while other ligands of the ASGPR are properly cleared (Roccatello et 
al, 1993).  The increased serum levels of IgA1 in IgAN patients may be thus 
attributed to the lack of clearance by the liver, as opposed to being entirely 
attributed to the increased antibody production.  
 
There is also enhanced binding of IgA1 to circulatory fibronectin (Davin et al, 
1991) and bacterial or viral lectins (Coppo, 1988) in IgAN.   
 
1.3.6.6 Galactose-Deficient IgA1-Containing Circulating Immune   
            Complexes are Boosted During Infection which Precedes IgAN Onset 
 
Indeed, the onset and exacerbation of IgAN i.e. recurrent macroscopic 
haematuria, is preceded by respiratory or gastrointestinal syndromes (Jessen et 
al, 1992; Berger & Hinglais, 1968).   
 
Increased levels of GalNAc-specific antibodies may result from preceding 
infection by microorganisms which express GalNAc-associated epitopes
 
(Tomana et al, 1999).  Many viruses such as respiratory syncytial, Epstein-Barr, 
and herpes viruses, as well as certain strains of Streptococci, express GalNAc on 
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their surface structures which may induce GalNAc-specific IgG, IgM, and IgA. 
Such GalNAc-specific antibodies in turn recognise and form complexes with 
galactose-deficient IgA1.  Circulatory immune complex formation is thus further 
compounded in patients with IgAN who have increased levels of galactose-
deficient IgA1 in the sera in comparison to healthy controls.   
 
Indeed, urinary levels of IgA/IgG immune complexes were noted to be higher in 
patients with IgAN than in patients with non-IgAN associated nephropathies and 
normal controls (Matousovic et al, 2006).   
 
Glycosylation confers protection against bacterial proteases through providing 
increased steric hindrance.  Following the molecular graphics modelling of 
dimeric IgA1, Bonner et al hypothesise that reduced galactosylation in IgA1 may 
enhance susceptibility to bacterial cleavage at the Fab regions resulting in the 
complete or partial removal thereof, followed by self-aggregation of the IgA 
molecule (2008).  In addition, under-glycosylation of IgA1 may result in the 
destabilisation of the extended hinge conformation, resulting in the displacement 




Multimer formation due to IgA1 aggregation following digestion by bacterial 
proteases was demonstrated in polymeric but not monomeric IgA1 (Almogren & 
Kerr, 2008).  This provides further evidence for the propensity of polymeric 
IgA1 in IgAN to aggregate and deposit in the mesangium. 
 
Galactose-deficient IgA1 may thus account for the increased levels of circulating 
immune complexes that remain uncleared from circulation and are hence prone 
to mesangial trapping.   
 
1.3.6.7 Galactose-Deficient IgA1 Selectively Deposit in the Renal   
            Mesangium  
             
Allen et al have demonstrated that the lectin binding of galactose-deficient IgA1, 
eluted from the glomeruli of IgAN patients, was markedly higher than that of the 
serum IgA1 of the same individual, and the serum IgA1 of other patients and 
controls (2001).  Such a finding indicates that galactose-deficient IgA1 
abnormally and selectively deposit in the glomerular mesangium of IgAN 
patients.  The study finding strongly suggests that abnormal IgA1 O-
glycosylation is not an epiphenomenon but may be directly implicated in the 
mesangial deposition of IgA.  
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Novak et al demonstrated that circulating immune complexes from patients with 
IgAN are less efficiently internalised by hepatoma cells (HepG2) and bind more 
efficiently to cultured mesangial cells than those from healthy controls (2002).    
 
Galactose-deficient IgA1 from patients with IgAN also have an enhanced in vitro 
affinity for, and bind efficiently to, mesangial matrix components such as type 
IV collagen, fibronectin, and laminin, due to carbohydrate interactions; resulting 
in the accumulation of IgA1 deposits in the mesangium (Coppo et al, 1995; 
Coppo et al, 1993).   
 
It is noted that galactose-deficient IgA1 in HSP, is restricted to patients with 
clinical nephritis (Allen et al, 1998). 
 
1.3.6.8 Pathogenic Effects of Galactose-deficient IgA1 Deposition in the   
            Renal Mesangium  
 
1.3.6.8.1 Up-regulation of Macrophage Migration Inhibitory Factor and Renin  
 
In vitro studies have demonstrated that the binding of IgA1 to mesangial cells 
leads to increased expression of growth factors, cytokines, and integrins, which 
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may enhance inflammatory injury.  Polymeric IgA1 from IgAN patients up-
regulates gene expression of renin and macrophage migration inhibitory factor in 
human mesangial cells, in a dose-dependent manner, leading to renal fibrosis 
(Lai & Leung, 2002). 
 
1.3.6.8.2 Down-regulation of Adiponectin  
 
Adiponectin, an adipocyte-derived secretory factor has anti-inflammatory 
effects, including the inhibition of adhesion molecules and cytokines (Wolf et al, 
2004).  Inoue et al reported suppression of adiponectin secretion in cultured 
human mesangial cells following stimulation with desialylated and 
degalactosylated IgA1 (2012).  In addition, a down-regulation of adiponectin 
expression was detected via immunofluorescence staining in the glomeruli of 
renal biopsy specimens from patients with IgAN compared to those with lupus 
nephritis.  Thus, local suppression of adiponectin by galactose-deficient IgA1 
could be involved in the regulation of glomerular inflammation and sclerosis in 






1.3.6.8.3 Mesangial Cell Proliferation 
 
Novak et al reported that enhanced mesangial cell proliferation was caused by 
galactose-deficient IgA1-containing circulating immune complexes from the sera 
of IgAN patients than uncomplexed IgA1 or immune complexes from healthy 
control subjects (2005).  In addition, circulating immune complexes containing 
higher levels of galactose-deficient IgA1 enhanced mesangial cell proliferation 
more efficiently than complexes with lower levels of galactose-deficient IgA1.  
Thus galactose-deficient IgA1-containing immune complexes have an enhanced 
ability to stimulate proliferation in mesangial cells. 
 
Novak et al demonstrated that circulating immune complexes from both adults 
and paediatric IgAN patients are galactose-deficient and that the large immune 
complexes abundant in galactose-deficient IgA1 play a pathogenic role by 
stimulating the proliferation of cultured human mesangial cells and increasing 
the production of the extra-cellular matrix protein, laminin (2011).  Complexes 
from paediatric patients with active disease stimulated the expression of IL-6 and 





1.3.6.8.4 Increased Apoptosis Rate and Nitric Oxide Synthesis 
 
Galactose-deficient IgA1, isolated from patients with IgAN, was shown to 
significantly increase the apoptosis rate and nitric oxide synthesis activity of 
cultured mesangial cells, compared to IgA1 from healthy controls (Amore et al, 
2001).  Amore et al have hypothesised that the extent of abnormal IgA1 
glycosylation, may determine the individual clinical course in IgAN (2001).   
 
1.3.6.8.5 Platelet-Activating Factor Induction  
 
An in vitro study demonstrated the pathogenic role of galactose-deficient IgA1 
as a mediator of podocyte changes that are associated with proteinuria in IgAN, 
through the induction of platelet-activating factor in mesangial cells (Coppo et 
al, 2010).  Platelet-activating factor effected the down-regulation of nephrin (an 
adhesion molecule that is critical to the glomerular permselectivity), and 
cytoskeletal F-actin reorganisation in human podocytes that were cultured with 
medium from mesangial cells treated with galactose-deficient IgA1 (that was 





1.3.6.8.6 Complement Activation 
 
A recent study using IgAN mouse models (grouped ddY (gddY) mice  and high 
serum IgA (HIGA) mice) demonstrated the pathogenic role of galactose-
deficient IgA1 as a mediator of immune complex formation and complement 
activation leading to the full-blown progression of IgAN (Hashimoto et al, 
2012).  The study results also demonstrate that the extent of galactose-deficiency 
could be a significant factor in determining the extent of pathology.  The gddY 
mice contained significantly higher levels of galactose-deficient serum IgA than 
the HIGA mice and controls and the galactose content was significantly lower in 
IgA molecules of gddY than HIGA mice.  
 
Glomerular activation of the classical, lectin and alternate pathways of 
complement was demonstrated by staining of C3, C5b-9, C1q, C4, mannose-
binding lectin (MBL)-A/C, MBL-associated serine protease-2, factor B and 
properdin; the staining was significantly stronger in gddY mice than in HIGA 
mice.  Thus, the greater activation of the complement pathways may be 




Whilst the levels of serum IgA are significantly higher in HIGA mice compared 
to gddY and control mice, the levels of serum IgA-IgG2/IgM and IgA-MBL-A/C 
immune complexes and polymeric IgA in gddY mice was significantly higher 
than that of HIGA and control mice.  The significantly greater number of 
immune complexes in gddY compared to HIGA mice despite the high serum IgA 
level in the HIGA mice, may be attributed to the greater degree of IgA 
hypogalactosylation deficiency which results in the formation of immune 
complexes.   
 
In addition, the percentage of the IgG and IgM deposition in the glomeruli was 
significantly higher in gddY than HIGA mice, suggesting that the enhanced 
degree of immune deposition may be attributed to the greater degree of IgA 
hypogalactosylation.   
 
Although the degree of glomerular IgA deposition was similar in gddY and 
HIGA mice, the extent of glomerular injury was more severe in gddY mice 
(defined by significantly greater albumin-creatinine ratio, severity of glomerular 
lesions, mesangial matrix expansion and glomerular type IV collagen 
expression).  Thus the greater degree of glomerular injury could be attributed to 
the greater degree of IgA hypogalactosylation in gddY mice.   
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1.3.7 Immunoglobulin Glycosylation 
 
1.3.7.1 Carbohydrate Proportion 
 
Depending on the immunoglobulin class, carbohydrate groups may form 
between two to fourteen percent of the immunoglobulin structure by weight 
(Wolfe, 1995).  IgA1 is highly glycosylated, containing 8% carbohydrate by 
weight.    
 
1.3.7.2 Enzymatic Addition of Carbohydrate Monomers 
 
Protein glycosylation is the most common and complex form of post-
translational modification.  Unlike the synthesis of nucleic acids and proteins, 
polysaccharide synthesis does not depend on template molecules.  A specific 
glycosyltransferase, an integral membrane glycoprotein of the endoplasmic 
reticulum or Golgi complex, catalyses the addition of a specific carbohydrate 






1.3.7.3 Transporter Proteins 
 
Before the addition of monosaccharide units to the protein, monosaccharides are 
activated in the cytoplasm by reaction with one of the nucleoside triphosphates: 
uridine triphosphate (UTP), cytidine triphosphate (CTP), or guanosine 
triphosphate (GTP).  The activated monosaccharides are transported across the 
endoplasmic reticulum and Golgi membranes by transporter proteins that 
exchange a nucleotide-monosaccharide complex from the outside for an unbound 
nucleotide on the inside. 
 
1.3.7.4 Glycan-Amino Acid Linkages  
 
Over 20 different types of glycan-amino acid linkages exist (Ju et al, 2011).  The 
two major types of glycosylation are N- and O-linked.  N-linked glycans are 
attached via N-Acetylglucosamine (GlcNAc) or GalNAc to a side chain amino 
group in an asparagine residue.  O-linked glycans are attached by an O-
glycosidic bond between GalNAc and the hydroxyl group of a threonine (Thr) or 
serine (Ser) residue (fig. 2).  N-linked glycans are commonly found in serum 
proteins while O-linked glycans are mainly restricted to membrane proteins and 
only a few serum proteins.  IgA1, in contrast to IgG, IgM and IgA2, contains O-
linked in addition to N-linked glycans.    
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1.3.7.5 O-Galactosylation of IgA1  
 
1.3.7.5.1 O-Galactosylation Sites 
 
The IgA1 hinge region consists of a unique 18 amino acid sequence (fig. 2).  The 
sequence contains a closely located series of nine potential O-glycosylation sites 
on each heavy chain, i.e. five serine and four threonine residues.  O-glycans 
occupy three threonine and two serine residues on each heavy chain (fig. 2).  
 
1.3.7.5.2 Core 1 β3-galactosyltransferase 
 
The intracellular enzyme core 1 β3-galactosyltransferase (β 1,3 GT) also known 
as T-synthase, catalyses the transfer of galactose from the nucleotide donor, 
uridine 5’ diphosphate-galactose (UDP-Gal), to the acceptor GalNAc that is O-
linked to serine or threonine residues in the IgA1 hinge region (Allen et al, 
1997).  This addition results in the formation of Galβ1,3GalNAc (fig. 2) which is 
referred to as the Thomsen-Friendenrich or T antigen; whilst the agalactosylated 
GalNAc moiety is referred to as the T antigen nouvelle or Tn antigen (Moreau et 
al, 1957).  Further extension of Galβ1,3GalNAc may include sialic acid (N-
Acetylneuraminic acid (NeuNAc)) in α 2,3 linkage with galactose to form 
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monosialyl-Galβ1,3GalNAc, or further α 2,6 linkage with GalNAc to form 
disialyl-Galβ1,3GalNAc (fig. 2) (Field et al, 1989; Baenziger & Kornfield, 
1974).   
 
1.3.7.5.3 Core 1 β3-Gal-T-specific molecular chaperone (Cosmc) 
 
The functionality of β 1,3 GT is dependent on the activity of Cosmc (Ju and 
Cummings, 2002).  The endoplasmic reticulum-localised Cosmc functions as a 
chaperone in the folding of β 1,3 GT (Ju et al, 2008).  Cosmc binds to newly 
synthesised β 1,3 GT and prevents its aggregation and subsequent degradation in 
the endoplasmic reticulum-associated degradation proteasome pathway.  
 
1.3.8 Abnormal Protein Glycosylation in Other Diseases 
 
In recent decades, abnormal protein glycosylation has become increasingly 







1.3.8.1 Rheumatoid Arthritis 
 
Axford et al described hypogalactosylation of the N-linked moieties of 
circulating IgG, as a result of reduced activity of the N-galactosylating enzyme, β 
1,4 galactosyltransferase, in patients with rheumatoid arthritis (1992).   
 
Ercan et al reported a significant correlation between the levels of abnormal IgG 
galactosylation and disease activity in rheumatoid arthritis; and that this 
abnormality predated disease onset and diagnosis (2010).   
 
1.3.8.2 Thomsen-nouvelle (Tn) syndrome 
 
In Tn syndrome, or Tn polyagglutinability syndrome, T- and B-lymphocytes, 
platelets, and or erythrocyte cell membrane proteins fail to express the T antigen, 
due to reduced β 1,3 GT activity (Cartron & Nurden, 1979; Cartron et al, 1978).  
Clinical manifestations include uraemia and thrombocytopenia.   
Although this failure of terminal galactosylation is similar to that described in 
IgAN, the antigenic determinants and corresponding antibodies differ.  In Tn 
syndrome, the Tn antigen consists of three adjacent GalNAc residues; a 
configuration that is not present in the IgA1 hinge region.  In Tn syndrome, the 
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anti-Tn antibodies belong to the IgM class, whilst the GalNAc-specific 
antibodies in IgAN also include the IgG and IgA1 isotypes.  Whilst disease-
associated O-glycosylation abnormalities have been described in membrane 
proteins, IgAN is the first disorder that describes such an abnormality in serum 
proteins. 
 
1.3.8.3 O-Glycans and Vascular Development 
 
Fu et al have demonstrated the significant role of O-glycans in vascular 
development (2008).  Fu et al generated mice that lack β 1,3 GT in endothelial 
and haematopoietic cells.  The lack of β 1,3 GT resulted in disorganised and 
blood-filled lymphatic vessels.  The chylomicron deposition, due to 
misconnected portal vein and intestinal lymphatic systems, caused fatty liver 
disease in pups.  Thus endothelial cell O-glycans control the separation of blood 
and lymphatic vessels during embryonic and postnatal development, in part by 
regulating the expression of podoplanin, a mucin-type transmembrane 








Expression of the Tn antigen has been associated with many forms of cancer (Ju 
et al, 2011).  Tn expression has been shown to positively correlate with the 
potential for metastasis and poor prognosis.   
 
In colon cancer, the Tn antigen that is present on Mucin 1, a glycoprotein on 
colon carcinoma cells, was shown to bind to macrophage galactose-type lectin 
(MGL) that is expressed by macrophages and tolerogenic dendritic cells.  The 
binding of the Tn antigen and MGL may thus lead to immunosuppression and 
escape of the tumour from immunosurveillance (Saeland et al, 2007).   
 
In two human cervical cancer specimens, and colon cancer and melanoma-
derived cell lines, the Tn antigen expression was associated with mutations in the 
gene encoding Cosmc (Ju et al, 2008).  This mutation could have resulted in 
inactivity of Cosmc and thus inactivity of the β 1,3 GT resulting in the formation 





1.4 Approaches to IgA1 O-Glycosylation Analysis 
 
Approaches that enable the analysis of IgA1 O-glycosylation include: lectin 
binding to the O-glycans on the complete IgA1 molecule; size analysis of 
isolated hinge region glycopeptides by matrix assisted laser desorption ionising 
mass spectroscopy (MALDI-MS); and separation of free O-glycans by 
chromatography or electrophoresis. 
   
1.4.1 Lectin Binding 
 
Lectins are soluble glycoproteins that are derived from plants and animals, and 
contain multiple binding sites which demonstrate strong and specific affinity for 
certain carbohydrate ligands (Wolfe, 1995).  Lectin binding assays exploit this 
characteristic in order to elucidate glycan structure.  The glycosylation pattern of 
a molecule is determined by the differential binding of lectins that are specific 
for individual saccharide residues on the intact molecule.  Lectin binding assays 
constitute the most widely used approach for IgA1 O-glycosylation analysis. 
 
Vicia villosa (VV) lectin, isolated from the seeds of the plant, binds to GalNAc 
in the absence of terminal galactose.  Thus increased VV binding is an indicator 
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of terminal D-galactose-deficient GalNAc.  Allen et al reported a significant 
increase in VV binding to serum IgA1 in patients with IgAN compared to age-
matched controls (1995).  Similar results were obtained with alternate GalNAc-
specific lectins viz. Helix aspersa (HA), Helix pomatia (HP), Caragana  
arborescens (CA), and Bauhinia purpurea (BP) in patients with IgAN (Allen et 
al, 1998; Tomana et al, 1997).   
 
Allen et al reported no difference in the N-glycosylation of IgA1 of IgAN 
patients and healthy controls with the use of the N-glycan specific lectins viz. 
Triticum vulgaris (TV) and Erythrina crystagalli (EC) (1995). 
 
Lectins with specificity to Galβ1,3GalNAc include Amaranthus caudatus (AC) 
and Peanut agglutinin (PNA) (Baharaki et al, 1996; Allen et al, 1995).  Jacalin 
lectin, isolated from Artocarpus integrifolia binds specifically to the IgA isotype 
(Roque-Barreira & Campos-Neto, 1985).  Jacalin binds to Galβ1,3GalNAc as 








1.4.2 Mass Spectroscopy 
 
The O-glycans of IgA1 are concentrated on a short stretch of the amino acid 
backbone in the hinge region, and therefore constitute a large percentage of the 
molecular mass of the isolated hinge glycopeptide.   
 
The MALDI-MS approach involves size analysis of the IgA1 hinge peptide with 
the attached O-glycans, following digestion of the IgA1 molecule (Iwase et al, 
1998; Iwase et al, 1996).   
 
Trypsin is used to digest the reduced and recarboxymethylated IgA1 molecule to 
yield a mixture of peptides, including the O-glycosylated hinge peptide.  The 
mass of the glycopeptide is in the range of 3.5 - 9.5 kDa with a carbohydrate 
content of up to 60% percent by mass.  The O-glycosylated hinge peptides are 
separated from the digest mixture by reverse phase high-performance liquid 
chromatography (HPLC) or Jacalin affinity chromatography.  The glycopeptide 
preparation is then subjected to MALDI-MS.  Since the molecular mass of the 
peptide is constant, the carbohydrate component of each glycopeptide is deduced 




Hiki et al reported a lack of terminal galactosylation of the IgA1 hinge O-
glycans from IgAN patients, following MALDI-MS analysis (1998).  Such data 
support the findings obtained via lectin binding assays.   
 
1.4.3 HPLC and Fluorophore-Assisted Carbohydrate    
         Electrophoresis (FACE)  
 
HPLC or FACE enables the identification and quantification of IgA1 O-glycans 
following the chemical or enzymatic release from IgA1 (Hu, 1995; Iwase et al, 
1992).   
 
Chemical release of the IgA1 O-glycans occurs by hydrazinolysis at 60°C; whilst 
N-glycans are retained, as temperatures in excess of 90 °C is required for N-
glycan release (Patel et al, 1993).   
 
GalNAc and Galβ1,3GalNAc moieties may be released from IgA1 by N-
Acetylgalactosaminidase (GalNAcase) and endo-N-Acetylgalactosaminidase (O-
glycanase) respectively (Allen et al, 1999).  Desialylation is a precursor for the 




1.4.3.1 Chromatography   
 
Gas liquid chromatography has been used to determine the total carbohydrate 
composition in individual monosaccharide units of the IgA1 glycan moieties, 
rather than the intact oligosaccharide chains, in patients with IgAN (Mestecky et 
al, 1993).  The vaporised sample constituents interact with the walls of the 
column and elution times are compared in order to determine the carbohydrate 
composition.  A decrease in the total IgA1 galactose content was demonstrated in 
IgAN.  This was interpreted as reduced O-glycosylation, as decreased Jacalin 
binding to IgA1 in IgAN patients was also observed. 
 
1.4.3.2 FACE  
 
Polyacrylamide gel electrophoresis is used to separate fluorophore-labelled free 
O-glycans.  The densities of the resultant bands under ultraviolet  light, provide a 
quantitative measure of the glycans present.  This approach has demonstrated a 
significant increase in the frequency of single GalNAc units in IgAN patients 




1.5 Advantages of the Lectin Binding Approach to IgA1 O-  
      Glycosylation Analysis 
 
The lectin binding approach is relatively rapid and inexpensive in comparison to 
other methods (Feehally & Allen, 1999).  The lectin binding assay is useful for 
screening large numbers of samples to compare group means.   
 
In addition, some lectin binding assays do not require purified IgA1 
preparations; while IgA1 purification constitutes the first step in other methods 
for IgA1 O-glycosylation analyses.  The purification process involved may 
influence the data obtained. 
 
In the chromatographic approach, harsh elution conditions which may damage 
the O-glycans are required to displace IgA1 from the columns.  In most studies, 
lectin binding assays are carried out in enzyme-linked immunosorbent assay 
(ELISA) - type systems.  IgA1 is immobilised on plastic immunoplates.  Thus, 
no elution is necessary, as IgA1 remains bound to the plate. 




1.6 Heritability of IgA1 O-Galactosylation 
 
The lectin binding assay has also been used to facilitate studies which identify 
genes that are associated with the undergalactosylation of IgA1 (Kiryluk et al, 
2010).  Kiryluk et al argue that identifying subgroups based on the galactose- 
deficient IgA1 level may be reflective of different disease aetiology and may 
thus reduce heterogeneity in linkage and genetic association studies in IgAN 
(2010).   
 
Recent serum IgA1 galactosylation studies in IgAN patients and their relatives 
suggest that abnormal serum IgA1 galactosylation is an inherited trait (Kiryluk et 
al, 2011; Hastings et al, 2010; Lin et al, 2009; Gharavi et al, 2008).   
 
Gharavi et al reported high serum galactose-deficient IgA1 in Caucasian patients 
with familial IgAN (i.e. biopsy proven IgAN in at least 2 family members) and 
47% of their at-risk relatives based on the assumption of autosomal dominant 
inheritance (2008).  Serum galactose-deficient IgA1 was also high in 78% of 
sporadic IgAN (i.e. biopsy proven IgAN in an individual whose family members 




In a cohort of Chinese IgAN patients and their first degree relatives, the level of 
serum IgA1 hypogalactosylation was significantly higher than that of normal 
controls, whilst no difference was found between normal controls and the 
spouses of IgAN patients (Lin et al, 2009).   
 
Hastings et al reported elevated serum galactose-deficient IgA1 levels in African 
American IgAN patients in comparison to controls (2010).  
 
Kiryluk et al demonstrated that serum hypogalactosylated IgA1 levels are highly 
inherited in paediatric IgAN patients (2011). 
 
1.7 Anti-galactose-deficient IgA1 Antibodies and IgA1   
      Glycoform Heterogeneity  
 
Although studies in Caucasian, Asian and African American patients 
demonstrated elevated levels of galactose-deficient IgA1 in both IgAN patients 
and their first degree relatives in comparison to controls (Hastings et al, 2010; 
Lin et al, 2009; Gharavi et al, 2008), an additional requirement for the 
pathogenic mesangial deposition of IgA1 is the presence of autoantibodies 
specific for galactose-deficient IgA1.  Uncomplexed galactose-deficient IgA1 
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does not affect cellular proliferation (Novak et al, 2007; Novak et al, 2005).  In 
IgAN, galactose-deficient-IgA1-specific autoantibodies are not genetically 
determined and are generated through somatic mutations (Suzuki et al, 2009).  
Suzuki et al reported an alanine to serine substitution in the complementarity-
determining region 3 of the variable region of the gene encoding the IgG heavy 
chain in IgAN patients, in comparison to healthy controls (2009).  Reversion 
from serine to alanine via site-directed mutagenesis of the IgG of an IgAN 
patient resulted in reduced binding of IgG to galactose-deficient IgA1 by 72%. 
The alanine to serine substitution in the IgG of a normal control resulted in 
increased binding to galactose-deficient IgA1 to 80% of that of the IgG of the 
IgAN patient.  
 
Furthermore, a series of IgA1-O glycoforms have been identified in polymeric 
IgA1 myeloma protein (Takahashi et al, 2012).  The IgA1 hinge regions are 
equally glycosylated but the O-glycosylation attachment sites are different.  
Mass spectrophotometric analysis of offline fractions revealed  two distinct 
isomeric hinge-region glycopeptides that contain a disaccharide attached to 
Ser232 in both fractions and a GalNAc monosaccharide attached to either 
Thr233 or Thr236 in an adjacent fraction.  In addition, other combinations of O-
glycan amino acid positional isomers involving Ser230, Thr233, and Thr236 
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were shown.  It is not known whether such glycoforms exist in 
undergalactosylated IgA1 from IgAN patients and relatives and if only certain 
glycoforms are pathogenic.   
 
It is not known, what proportion, if any, of such asymptomatic relatives with 
elevated levels of galactose-deficient IgA1 that may develop IgAN in the future. 
 
1.8 Severity of IgAN  
 
1.8.1 Most Common Glomerulonephritis and Leading Cause of   
         ESRD in Developed Countries  
 
IgAN is the most common form of primary glomerulonephritis, and a leading 
cause of chronic kidney disease and end-stage renal disease in developed 
countries (Levy & Berger, 1988).   
 
ESRD is a major public health problem.  It affects 1 in 1000 individuals with an 
annual death rate of 20%.  10 to 50% of patients with IgAN may progress to 
ESRD within 20 years of disease onset (Galla, 1995).  In certain patients, 
however, the rate of deterioration is especially rapid.  These patients require 
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either dialysis or kidney transplantation (Julian et al, 1999).  During dialysis, 
renal changes may continue (Lawler, 1991).  While renal transplantation may 
return renal function, it does not remove the cause of the recipient’s original 
disease.  Renal transplantation is not a cure, but a treatment of ESRD.  In centres 
that conducted routine biopsy following transplantation, 50 to 60 % of the 
recipients were reported to experience histological recurrence (Odum et al, 1994; 
Berger et al, 1984).   
 
1.8.2 Recurrence Post-transplantation 
 
Recurrent IgAN following transplantation has previously been assumed to 
follow a benign clinical course, but recent studies have suggested that it is a 
significant contributor to graft loss (Moroni et al, 2013).  Clinically important 
recurrence leading to graft loss has been reported in about 5 to 16% of recipients, 
(Moriyama et al, 2005; Freese et al, 1999; Frohnert et al, 1997; Ohmacht et al, 
1997; Odum et al, 1994).  Recurrent IgAN may not be prevented either 
histologically or clinically, by immunosuppression with corticosteroids, 





1.8.3 Non-specific and Non-Curative Treatment 
 
Current treatment for IgAN includes the use of immunomodulators that suppress 
the humoural and cell-mediated immune systems.  These include steroid therapy 
(Pozzi et al, 1999)
 
which is recommended for nephrotic patients with mild 
histological changes and preserved renal function; fish oil
 
supplements (FOS) 
(Donadio et al, 1994) which contain a high concentration of Omega 3 fatty acids, 
and are recommended for patients with slowly progressive disease; and a 
combination of steroids and cyclophosphamide which may be effective in 
patients with focal necrotising lesions, often accompanied by crescents and a 
rapid decline in renal function.    
 
However, steroids, FOS and other immunocytoreductive agents such as 
cyclophosphamide, are non-specific immunomodulators, and thus fail to target 
specific components that are unique to the molecular pathogenesis of IgAN.  
Such agents fail to halt the progression of the disease (Hogg & Wyatt, 2004).  
FOS may only delay progression for a few years, rather than permanently 
preventing progressive disease (Novak et al, 2002).  The use of high dose 
steroids over long course therapy is associated with significant morbidity (Novak 
et al, 2002).   
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Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers 
are used to control blood pressure and reduce proteinuria; and are thus 
symptomatically therapeutic as opposed to being curative.  Such agents do not 
halt the progression of the disease, and there is no benefit offered in the 
utilisation of such agents in early IgAN.  In an open-label randomised control 
trial, Li et al demonstrated that treatment with 2.5 mg daily of ramipril, an ACE 
inhibitor, for 5 years is non-beneficial in early IgAN patients with minimal 
proteinuria, and normal blood pressure and renal function (2013).  Li et al 
suggest starting ACE inhibitors angiotensin-receptor blocker treatment when the 
proteinuria level is above 0.5 g/day (2013).  Throughout the study period, the 
blood pressure of the treatment group was slightly lower than that of the control 
group.  At 60 months, the event-free survival was slightly higher for the 
treatment group at 60 months of follow up.  The proteinuria-free survival was 
similar in both groups; impaired renal function did not develop in either group 
but the glomerular filtration rate decline was similar.  
 
Thus, no specific therapies for IgAN have been developed, and there is currently 





1.8.4 The Pathogenesis of IgAN is Incompletely Understood 
 
IgAN is a complex multi-factorial disorder for which the underlying 
pathogenetic mechanisms are incompletely understood.  The mesangial 
deposition of IgA1 is the initiating event for the pathology in IgAN (Barratt et al, 
2004).  The elucidation of the key events that enable or promote mesangial 
deposition is critical for the development of specific therapies that target the 
underlying aberrancies.   
 
1.9 Study Aim and Hypothesis 
 
The significant contribution of IgAN to ESRD worldwide, and the absence of 
curative therapy, reflects the importance of elucidating the key pathological 
mechanisms responsible for mesangial IgA1 deposition.   
 
In the case of such a complex multi-factorial disorder, the determination and 
comparison of the underlying pathogenetic mechanisms among various 
populations globally, is essential for the advancement of the understanding of the 
disorder and the eventual development of specific therapies.  Hitherto, 
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experimental data on the pathogenesis of IgAN for any country in the African 
continent is scarce.  
 
It is hypothesised that there is a difference in the O-glycosylation patterns of 
serum IgA1 between IgAN patients and healthy controls of different ethnic 
origins in the South African population.  It is hypothesised that the serum IgA1 
from patients with IgAN are hypogalactosylated and thus abnormal 
glycosylation is a pathogenetic mechanism in IgAN patients in the study 
population.   
 
IgA1 O-galactosylation comparisons between racial groups; between end-stage 
and pre-dialysis patients; and between gender, was investigated, although it is 
noted that the sample size for such comparisons are too low for hypothesis 
generation and valid conclusions in this study.  Nonetheless, in a statistically 
valid sample size, it would be hypothesised that IgA1 O-galactosylation is 
significantly higher in males than females, based on a worse IgAN prognosis for 
males and the pathogenic role of galactose-deficient IgA1 in promoting 
mesangial deposition and renal injury and hence a progression of the disease; it 
would be hypothesised that IgA1 O-galactosylation is significantly higher in the 
end-stage than pre-dialysis IgAN patients due to the pathogenic role of 
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galactose-deficient IgA1 in the promotion of mesangial deposition and injury 
and hence a progression to end-stage IgAN.  Hypotheses based on racial 
comparison are precluded by the paucity of data in the literature on IgA1 O-
galactosylation studies among different racial groups; although since the IgAN 
prognosis was reported to be more severe in an Asian group in comparison to 
non-Asians (Barbour et al, 2013), it may be hypothesised that there is a 
significantly greater level of IgA1 O-galactosylation in Indian IgAN patients in 
comparison to other race groups.    
 
1. South Africa consists of a uniquely multi-ethnic population.  The study 
aims to elucidate and comparatively analyse the O-glycosylation patterns 
of serum IgA1 between IgAN patients and healthy controls of different 
ethnic origins in KZN, South Africa, and thus provide pathogenetic data 
for IgAN.  The study thus aims to provide the first O-glycosylation data 
for IgAN for the African continent.   
 
Since the study aims to investigate an initial event which may be responsible for 
the mesangial deposition of IgA1, data from the study may form the basis for 
research into the development of specific therapies. 
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CHAPTER 2 - METHODS 
 
   2.1 Concise Study Design 
 
Following submission of the study proposal and ethics application, approval was 
attained.   
 
Subsequently, blood samples were obtained following informed consent from 
South African adult biopsy-proven IgAN patients.  Such patients were of 
African, Caucasian, Indian, Coloured and Mixed-Race descent, and were 
attending the Inkosi Albert Luthuli Central Hospital in Durban, KZN.   
 
IgAN patients that were on dialysis or received a transplant were noted from a 
database at the IALCH. 
 
Blood and urine samples were obtained following informed consent from adult 
volunteers of African, Caucasian, Indian, and Coloured descent, from various 
locations in Durban, KZN.  Volunteers were screened for renal disease via the 
urine-dipstick test.    
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Serum IgA1 O-glycosylation analysis was performed on the serum samples, 
using the VV lectin binding approach in an ELISA-type system.  The statistical 
analysis of the raw data was performed using the GraphPad Instat
®
 3.0 statistical 
package (La Jolla, California; United States of America (USA)).   
 
2.2 Ethical and Study Approval  
 
Ethical approval was attained following submission of the study proposal and 
ethics application to the Biomedical Research Ethics Committee.  Study 
approval was attained following submission of the study proposal and ethics 
approval to the Postgraduate Education Committee of the NRMSM, the IALCH 
Manager, and the KZN Department of Health.     
 
2.3 Participant Recruitment  
 
2.3.1 IgAN Patient Participants   
 
The Chronic Renal Programme database at the renal clinic at the IALCH in 
Durban, KZN, was first accessed in 2006 to identify patients with IgAN.  The 
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database contained a list of renal patients that were either accepted, or not 
accepted, onto the chronic renal programme at the clinic.  The database 
contained 1769 renal patients.  Biopsy was not carried out in all of the patients.  
30 patients had biopsy-proven IgAN.     
 
However, a significant proportion of the 30 IgAN patients declined participation 
in the study, whilst some were deceased, or transferred out to another hospital.  
IgAN patients have unique clinic visit dates, i.e. all patients do not attend the 
clinic on the same day.  The frequency of visits is as low as once a year for some 
patients.  The recruitment process for patient participants thus spanned a period 
of 6 years; in order to access patients, and to attain new IgAN patients to obtain a 
statistically significant number of participants.  Patients were recruited during 
2007, 2009, and 2011.     
 
IgAN patients were approached when they attended the Renal Clinic.  A 
Phlebotomist was hired for the extraction of the blood samples from some 
patients that were accessed at their homes.  IgAN patients were informed about 
the study verbally and through the provision of detailed information documents 
in the spoken language of the patient.  Each patient participant signed an 
informed consent form. 
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A blood sample of 4 ml was extracted at the clinic by the attending Sister from 
each participant.  An exception included one participant who provided 2 
samples: 1 in 2007 and subsequently in 2009.   
 
The blood sample was immediately transported in a polystyrene box to the 
Medicine Laboratory at the NRMSM, UKZN, for processing.   
 
2.3.2 Control Participants and Urinalysis 
 
Control participants were recruited from two independent work institutions in the 
Durban area.  The potential participants were informed about the study verbally 
and via the provision of detailed information documents in the spoken language 
of the potential participant.  Each volunteer signed an informed consent form. 
Since the presence of blood and or protein in the urine may be an indicator of 
renal disease, a fresh urine sample was obtained from each control volunteer and 
immediately subjected to urinalysis at the work site.  Urinalysis was conducted 
via the Makromed urine dipstick test which enables the detection of blood and 
protein that may not be visible to the naked eye.  A colour change of the 
indicator dye at the relevant areas on the test strip indicates the presence of blood 
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or protein in the urine.  The colour change was noted between 45 to 60 seconds 
following insertion of the strip into the urine sample.   
 
Control volunteers with negative urinalysis results were recruited as control 
participants, from whom blood samples were subsequently obtained.  Volunteers 
with positive urinalysis results for the presence of blood and or protein were 
excluded from the study and were referred to seek medical attention.   
 
A Phlebotomist was hired for the extraction of a 4ml blood sample from each of 
the control participants at the work site.  Recruitment of control participants took 
place during 2008 and 2009. 
 
2.4 Participant Description   
  
2.4.1 Control Population Description 
 
The control population consisted of 20 participants.  The control population 
included participants of African, Caucasian, Coloured, and Indian descent 
(Appendix 2; table 1) in the proportion of 30%, 15%, 5% and 50% respectively 
(Appendix 3; table 2).  The median and mean age of the control population was 
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32 and 31 respectively (Appendix 4; table 3).  The age range was 19 to 49 
(Appendix 3; table 2).  Males constituted 45% of the control population 
(Appendix 4; table 3). 
 
2.4.2 Experimental Population Description 
 
The experimental population i.e. the IgAN patient population consisted of 19 
participants.  The patient population contained participants of African, 
Caucasian, Coloured, and Indian descent, and one individual of mixed race 
(Indian and Caucasian) (Appendix 5; table 4) in the proportion of 10.53, 10.53, 
15.79, 57.89 and 5.26% respectively (Appendix 6; table 5).  The median and 
mean age of the experimental population was 43 and 46 respectively (Appendix 
4; table 3).  The age range was 29 to 66.  Males constituted 63 % of the 
experimental population (Appendix 4; table 3).   
 
Of the 19 patients, 53% were at the end-stage, i.e. on dialysis and or having been 
transplanted.  The end-stage IgAN patient population included participants of 
African, Caucasian, Coloured and Indian descent (Appendix 5; table 4).  The 




2.5 Whole Blood Extraction and Separation  
 
2.5.1 Whole Blood Extraction 
 
4 ml of whole blood was extracted from each participant into two EDTA 
anticoagulated tubes by the attending Sister or Phlebotomist.  The purple top 
tubes were labeled with the name of the participant and transported immediately 
to the NRMSM Medicine laboratory in a polystyrene box for whole blood 
separation into plasma and serum.   
 
2.5.2 Whole Blood Separation  
 
2.5.2.1 Sample Encoding 
 
For the maintenance of participant confidentiality, each participant was allocated 
a unique code consisting of letters and numbers (Appendix 2; Appendix 5).  This 
unique code was used to label the sample tubes and cryogenic vials.  Participant 
codes were maintained during the experimental procedures and subsequent data 




2.5.2.2 Whole Blood Separation and Serum Storage 
 
Under the laminar flow cabinet, whole blood from the participant’s pair of purple 
top tubes was pipetted into the appropriately labeled 15 ml polypropylene 
centrifuge tube (Corning; New York, USA).  
 
Centrifuge tubes were placed opposite each other in the centrifuge (Hettich 
Universal/K25; Tuttlingen, Germany) for separation of whole blood into plasma 
and serum at room temperature (25ºC) and a rotational speed of 2500 revolutions 
per minute (rpm) for 10 minutes. 
 
Following centrifugation, the serum from the centrifuge tube was pipetted into a 
series of appropriately labelled cryogenic vials (Corning; New York, USA) and 
stored in the Medicine laboratory freezer at -70ºC.  IgA glycosylation may 
remain unchanged for more than 10 years in a stored frozen serum sample 







2.6 IgA1 O-Glycosylation Analysis 
 
2.6.1 Experimental Design 
 
The analysis of serum IgA1 O-glycosylation was carried out using a lectin-
binding assay in an ELISA-type system (Allen et al, 2001). 
 
96-well immunoplates were coated with rabbit anti-human IgA antibody, 
followed by washing, and blocking with 2% fetal calf serum (FCS) in phosphate-
buffered saline (PBS).  Serum samples were diluted to 1:100 in PBS and 50μl of 
each sample was applied to duplicate wells to capture IgA1.  Biotinylated VV 
lectins were applied to each well.  Lectin binding was detected with horseradish 
peroxidase (HRP)-conjugated avidin.  The reaction was developed with o-
Phenylenediamine (OPD)/H2O2 substrate and stopped with 1 mol/l H2SO4.  The 
results were read as absorbance (A) at 490 nm.  The lectin binding of serum 







2.6.2 Reagent Preparation and Storage 
 
2.6.2.1 Autoclaving  
 
Glass bottles, measuring cylinders, deionised water, and pipette tips were 
autoclaved for 20 minutes at 121 ºC (Erma; Tokyo, Japan). 
 
2.6.2.2 Preparation of Primary Antibody in Coating Buffer 
 
Rabbit anti-human IgA (5g/l) (Dako; Glostrup, Denmark) was diluted to 1:500 
(10μg/ml) in coating buffer. 
 
One capsule of 0.05M carbonate/bicarbonate buffer (pH 9.6) (Sigma; St. Louis, 
USA) was opened to release the carbonate/bicarbonate powder into an 
appropriately labelled autoclaved bottle with 100 ml autoclaved deionised water, 
as per reconstitution instructions on the product specification sheet.  The bottle 





The carbonate/bicarbonate buffer solution and carbonate/bicarbonate buffer 
capsules were stored at room temperature.   
 
24.950 ml of carbonate/bicarbonate coating buffer was added to the 
appropriately labelled 50 ml polypropylene tube (Sterilin; Newport, United 
Kingdom).   
 
Storage conditions for the primary antibody i.e. Rabbit anti-human IgA includes 
refrigeration at 2-8ºC.  The primary antibody was stored at 4ºC.  The vial 
containing 1 ml of Rabbit anti-human IgA was removed from the refrigerator 
and tapped gently before being opened.  50 µl of Rabbit anti-human IgA was 
added to the polypropylene tube containing the 24.950 ml of carbonate/ 
bicarbonate buffer to produce the primary antibody in coating buffer in a 1:100 
dilution.  The tube containing the primary antibody/coating buffer mix was 
gently tapped at the bottom followed by vortexing (Vortex Genie; New York, 
USA) for approximately 2 seconds at speed setting ‘3’. 
 





2.6.2.3 Preparation of PBS Solution  
 
PBS solution (pH 7.4) was prepared by dissolving 1 PBS tablet (Sigma; St. 
Louis, USA) in 200 ml of autoclaved deionised water (as per instruction from the 
product specification sheet) in an appropriately labelled autoclaved glass bottle, 
using a magnetic stirrer (Ikamag; Staufen, Germany) at room temperature for 
approximately 10 minutes.     
 
The PBS solution was stored in the refrigerator at 4ºC.  The PBS tablets were 
stored at room temperature. 
 
2.6.2.4 Preparation of Washing Buffer (PBS/0.3M NaCl/ 0.1% Tween 20) 
 
PBS solution (pH 7.4) was prepared by dissolving 5 PBS tablets in a litre of 
autoclaved deionised water in an appropriately labelled autoclaved glass bottle, 
using a magnetic stirrer at room temperature for approximately 10 minutes.   
 
The PBS solution was stored in the refrigerator at 4ºC.  The PBS tablets were 




20.75 g of NaCl (Sigma-Aldrich; Milwaukee, USA) was massed using a mass 
balance (Adam AFP- 3100 L; Danbury, USA) in an autoclaved glass bottle.  1 
litre of PBS solution was added to the bottle, and the contents was dissolved 
using a magnetic stirrer at room temperature for approximately 8 minutes.   
Following dissolution, 1 ml of Tween 20 (Sigma; Steinheim, Germany) was 
added and allowed to dissolve for approximately 5 minutes using the magnetic 
stirrer.   
 
The washing buffer was stored in the refrigerator at 4ºC. 
 
2.6.2.5 Preparation of Blocking Agent (2% FCS in PBS) 
 
FCS (Highveld Biological; Johannesburg, South Africa) was stored at -70ºC.  
The FCS was placed in the refrigerator to thaw overnight prior to use.   
 
500µl of FCS was added to an appropriately labelled 50 ml polypropylene tube 
containing 24.500 ml of PBS.  The tube was then vortexed for approximately 5 
seconds at speed setting ‘3’.    
 
The 2% FCS in PBS was stored in the refrigerator at 4ºC. 
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2.6.2.6 Reconstitution of Biotinylated Lectin (VV) and Dilution of   
            Biotinylated VV Lectin in PBS (1:500) 
 
Biotinylated VV lectin (2 mg) (Vector; California, USA) was stored refrigerated 
at 4ºC.  1ml of autoclaved deionised water was added to the vial containing 
Biotinylated VV lectin, for reconstitution.  The vial was gently tapped and 
vortexed for approximately 3 seconds at speed setting ‘3’.   
 
Reconstituted Biotinylated VV lectin was stored refrigerated at 4ºC. 
 
10 µl of reconstituted Biotinylated VV lectin was added to 4990µl of PBS in a 
15 ml tube (1:500).  The tube was gently tapped and vortexed for approximately 
2 seconds at speed setting ‘3’.   
 
2.6.2.7 Dilution of HRP-conjugated Avidin in PBS (1:2000) 
 
Horseradish Peroxidase Avidin D Concentrate (5 mg) (Vector; California, USA) 




19.990 ml of PBS was added to an appropriately labelled 50 ml polypropylene 
tube.  10 µl of HRP-avidin was added to the tube.  The tube was gently tapped 
and vortexed for approximately 5 seconds at speed setting ‘3’.   
 
The HRP-avidin/PBS was stored refrigerated at 4ºC.   
 
2.6.2.8 Preparation of OPD/ H2O2 Substrate 
 
OPD tablets (Dako; Glostrup, Denmark) were stored refrigerated at 4ºC.  The 
temperature range for storage is 2-8 ºC.   
 
The bottle of OPD tablets was removed from refrigeration and allowed to stand 
for 10 minutes at room temperature prior to opening.  
 
The tablet was removed with the aid of a pair of tweezers.  The tablet was placed 
in an appropriately labelled, foil-covered 15 ml polypropylene tube containing 
3ml of deionised autoclaved water.  The foil-covered tube was used to protect 
the substrate solution from direct light.  The vial was gently tapped at the bottom 




30% H2O2 solution was stored refrigerated at 4ºC and protected from light, to 
preserve the activity.  Immediately before use, 1.2µl of 30% H2O2 solution (500 
ml) (Sigma; Steinheim, Germany) was pipetted into the OPD solution.  The 
substrate solution was used within an hour of preparation, as per instructions 
from the Dako OPD specification sheet.  
 
2.6.2.9 Preparation of 1M H2SO4 (Stopping Solution)                   
 
At the fume cupboard, 20ml of autoclaved deionised water was added to a 100 
ml measuring cylinder.  5.6 ml of H2SO4 (95-97%) (Merck; Darmstadt, 
Germany) was added to the 100 ml measuring cylinder.  Autoclaved deionised 
water was added to the 100 ml measuring cylinder  to the final volume of 100 
ml.  The H2SO4 solution was poured into an appropriately labelled 100 ml glass 
bottle.  The bottle containing the H2SO4 solution was gently swirled and stored at 










2.6.3.1 Coating of the Plate with Primary Antibody 
 
Costar 96-well plates (Corning; New York, USA) were stored at room 
temperature.   
 
Prior to each experiment, a sketch of the plate containing the wells designated to 
specific samples and positive and negative controls, was prepared.   
 
At room temperature at the bench top, 100 µl of refrigerated primary antibody in 
coating buffer was added to the wells designated to receive samples and controls.   
 
The plate was immediately sealed with a polyethylene wrap (Glad; Babelegi, 










The polyethylene wrap was carefully removed and discarded following the 24 
hour incubation period.  The plate was washed 4 times with 300 µl of wash 
buffer per well with the aid of a microplate washer (Anthos Fluido; Cambridge, 
United Kingdom) at room temperature.   
 
The plate was turned over onto a stack of paper towel to remove excess fluid.   
 
The base of the tube containing 2% FCS in PBS was tapped gently for 
approximately 4 seconds.  100µl of refrigerated 2% FCS in PBS was added to 
each well.  The plate was then sealed with polyethylene wrap and left to incubate 
for 1 hour on the bench-top at room temperature.   
 
Bovine serum albumin is generally used as the blocking agent in O-glycosylation 
lectin binding studies of IgA1 (Allen et al, 2001).  However, in this study, fetal 
calf serum albumin was used instead.  For plate 12 (Appendix 8), however, 
bovine serum albumin was used instead of fetal calf serum in the preparation of 




2.6.3.3 Serum Sample Preparation 
 
The cryogenic vials containing the desired frozen serum samples were removed 
from storage and left to thaw on the bench-top at room temperature for 
approximately 10 minutes.   
 
1.5 ml microcentrifuge tubes (Eppendorf; Hamburg, Germany) were labelled 
according to the serum sample and the designated well.   
 
495µl of PBS was added to each microcentrifuge tube.  5µl of serum was added 
to the appropriately labelled microcentrifuge tube containing PBS (1:100).   
 
Each tube was vortexed for approximately 6 seconds at speed setting ‘4’.  The 
base of the tube was tapped 22 times.  
 
50µl of serum/PBS was added to the designated wells in duplicate.  50 µl of PBS 
was added to the negative control wells.   
 
The plate was carefully sealed with polyethylene wrap and incubated overnight 
(16 hours) at 4ºC in the refrigerator.  
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2.6.3.4 Lectin Application 
 
Following the 16 hour incubation period, the plastic wrap was carefully removed 
and discarded.  The plate was washed 4 times with 300 µl of wash buffer per 
well, with the aid of a microplate washer, at room temperature.  The plate was 
turned over onto a stack of paper towel to remove excess liquid.   
 
50 µl of Biotinylated VV lectin/PBS was added to each well.  The plate was 
sealed with polyethylene wrap and left to incubate for 90 minutes at room 
temperature on the bench-top.   
 
2.6.3.5 Horseradish Peroxidase/Avidin Application 
 
Following the 90 minute incubation period with the Biotinylated VV lectin/PBS, 
the polyethylene wrap was carefully removed and discarded.  The plate was 
washed 4 times with 300 µl of wash buffer per well, with the aid of a microplate 
washer, at room temperature.  
 




50µl of HRP/Avidin/PBS was added to each well.  The plate was sealed with 





Following the 90 minute incubation period with HRP/Avidin/PBS, the 
polyethylene wrap was carefully removed and discarded.  The plate was washed 
4 times with 300 µl of wash buffer per well, with the aid of a microplate washer, 
at room temperature.  
 
Prior to the washing of the plate, the vial containing the OPD was removed from 
the fridge and left to stand for 10 minutes on the bench-top at room temperature.  
 
3ml of autoclaved deionised water was added to a 15 ml foil-covered propylene 
tube.  Using a pair of tweezers, an OPD tablet was added to the tube.  The tube 
was gently tapped and vortexed for approximately 4 seconds at speed setting ‘3’.   
 
1.2µl of 30% H2O2 solution was added to the vial containing the OPD solution 
immediately before the addition of OPD/ H2O2 substrate  to each well.  The vial 
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was gently tapped and vortexed again for approximately 3 seconds at speed 
setting ‘3’.   
 
The substrate solution was applied to the plates at 50µl per well.  Excess 
substrate solution was discarded as hazardous waste.   
 
The plate was covered with foil and placed on the microplate shaker (IKA 
Schuttler MTS 4; Staufen, Germany) at 100 rpm at room temperature for 10 
minutes for the colour development.  An olive-green/brown colour results (fig. 
3).  The reaction was stopped with the addition of 1M H2SO4.  A light 
pink/orange colour results upon addition of stopping solution (fig. 4). 
 
Figure 3:  96 well Immunoplate Following Agitation after Addition of 




Figure 4:  96 well Immunoplate Following Addition of Stopping Solution 
(1M H2SO4) 
 
2.6.3.7 Plate Reading 
 
Following the addition of stopping solution, the plate was transferred to the plate 
reader (Anthos 2010; Cambridge, United Kingdom).  The plate was read at 490 
nm at room temperature.  
 
A print-out of the absorbance values at 490 nm was attained.  The plate was 




2.6.4 Statistical Analyses of the Absorbance Data 
 
Since the VV lectin binds to ungalactosylated GalNAc i.e. the Tn antigen, 
greater lectin binding is an indicator of IgA1 O-hypogalactosylation, which 
results in a higher absorbance value.  
 
The mean absorbance value for each duplicate sample was calculated and used 
for the analyses (Appendix 8; table 7, table 8).  
 
The GraphPad Instat 3.0 statistical software was used to compare the absorbance 
data between and within experimental and control groups.  Where the 
distribution of data did not pass the normality test in the groups to be compared, 
a non-parametric test called the Wilcoxon matched-pairs test, was used for 
comparison.  The Mann-Whitney test was used to assess for a statistically 
significant difference between groups; a p value of less than 0.05 was considered 
to be statistically significant.  The Spearman’s correlation test was used to assess 






2.6.4.1 IgAN and IgA1 O-Galactosylation  
 
For each experiment, the mean absorbance value for the IgAN group and control 
group was compared.   
 
2.6.4.2 IgA1 O-Galactosylation and Race 
 
Since the IgAN group was predominantly Indian (table 1), for each experiment 
the mean absorbance value for the Indian IgAN group was compared to that of 
the other race groups combined.   
 
2.6.4.3 IgA1 O-Galactosylation and Gender 
 
The mean absorbance value for the male and female IgAN sub-groups was 








2.6.4.4 IgA1 O-Galactosylation in Pre-dialysis versus End-stage IgAN  
            Patients 
 
For each experiment, the mean absorbance value for the pre-dialysis IgAN 
patients was compared to that of the end-stage renal disease patients. 
 
2.6.4.5 IgA1 O-Galactosylation and Age in IgAN Patients  
 
The Spearman correlation test was used to assess for a possible correlation 
between age and the level of IgA1 O-galactosylation in IgAN patients.  
 
 
CHAPTER 3 - RESULTS 
    
  3.1 IgAN and IgA1 O-Galactosylation 
 
   The distribution of the data did not pass the normality test.    The average means         
   of the experiments for the IgAN group is 0.3678 ± 0.0790 (standard error of the  
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   mean (SEM) and is statistically significantly greater than the normal control   
   group which is 0.2969 ± 0.0586 (SEM); (p = 0.0076) (fig. 5).  Thus, in this  
   population of IgAN patients, the serum IgA1 is hypogalactosylated.      
  
 












































3.2 Participant Description 
 













Number (No.); Not Applicable (N/A); End Stage Renal Disease (ESRD). 
 IgAN  Control  
No. Participants 19 20 
Male (%) 63 45 
Mean Age  46 32 
IgAN Patients at ESRD (%) 53 N/A 
African  2 6 
Caucasian  2 3 
Coloured (Mixed) 3 1 
Indian/Caucasian (Mixed) 1 0 
Indian 11 10 
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3.3 IgA1 O-Galactosylation and Race 
    
  
Figure 6:  IgA1 O-Hypogalactosylation in Indian Versus Non-Indian IgA  
Nephropathy Patients 
 
The distribution of the data did not pass the normality test.  There was no   
statistically significant difference between the average means of the experiments  
for the IgAN patients of the Indian group and that of the Non-Indian group (p =  
0.678) (fig. 6).  The mean for the Indian IgAN patients was: 0.1225 ± 0.02220.   
The mean for the Indian control group was 0.10657 ± 0.01039.  The mean for the  
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non-Indian control group was 0.07020 ± 0.00968. 
 
3.4 IgA1 O-Galactosylation and Gender 
 
The distribution of the data did not pass the normality test.  Although the average  
of the absorbance means, corresponding to the level of IgA1 O- 
hypogalactosylation, was higher in male than female IgAN patients, there was no  
statistically significant difference between the level of IgA1 O-hypogalactosylation  
in male and female IgAN patients (fig 7) ( p = 0.8501).  Fig. 7 and fig. 8  
demonstrate that the level of IgA1 O-hypogalactosylation is higher in IgAN  
patients than in controls. 
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  Figure 7:  IgA1 O-Hypogalactosylation in Male Versus Female IgAN Patients 
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Figure 8:  IgA1 O-Hypogalactosylation in Male Versus Female Controls 
 
3.5 IgA1 O-Galactosylation in Pre-dialysis Versus End-stage  
      IgAN Patients 
 
The distribution of the data did not pass the normality test.  Although the level of  
IgA1 O-hypogalactosylation was higher in end-stage IgAN patients compared to  
pre-dialysis patients, there was no statistically significant difference between the  
level of IgA1 O-hypogalactosylation in pre-dialysis and end-stage IgAN patients  
(fig. 9).  The p value is 0.6685.   







































3.6 IgA1 O-Galactosylation and Age in IgAN Patients 
 
No correlation was found between IgA1 O-galactosylation and age in IgAN  
patients (IgAN: Spearman R = 0.1258; p = 0.5973 (fig. 10); Controls: Spearman R  
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Figure 9: IgA1 O-Hypogalactosylation in End-stage Versus Pre-
dialysis IgAN Patients 
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Figure 10:  IgA1 O-Hypogalactosylation and Age in IgAN Patients 
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CHAPTER 4 - DISCUSSION 
 
4.1 Abnormal Serum IgA1 O-Galactosylation in a Multi- 
      ethnic IgAN Population in KZN, South Africa 
 
In this study, the O-galactosylation of serum IgA1 in IgAN patients from KZN,  
South Africa was analysed using an ELISA-type lectin binding assay.  In the study  
population, the IgAN patients exhibited abnormal serum IgA1 O-galactosylation, as  
defined by a statistically significantly greater level of hypogalactosylation in  
comparison to that of the controls (p < 0.05) (fig. 5).  Terminal D-galactose is the  
ligand of the hepatic ASGPR which mediates endocytotic clearance of IgA1 from  
the circulation following recognition of D-galactose.  In IgAN however, the  
galactose-deficient IgA1-containing immune complexes, may thus escape hepatic  
clearance and pathogenetically deposit in the renal mesangium, effecting  






4.2 IgA1 O-Galactosylation and Race in IgAN  
 
4.2.1 Sample Size  
 
The recruitment of IgAN patients for the study was hindered by: the number of  
individuals with IgAN that presented to the IALCH, the number of renal  
patients attending the IALCH Renal Unit that were biopsied, and the number of  
IgAN patients at the IALCH that consented to the study.  Some individuals with 
IgAN remain undiagnosed until an advanced stage of the disease is reached.  Not  
every renal patient at the IALCH Renal Unit was biopsied.  Certain conditions  
such as shrunken kidneys, for example, may preclude biopsy.  Thus, statistically  
comparable numbers of IgAN patients for each ethnic group was not attained.   
 
Since the IgAN group in this study was predominantly of Indian ethnicity, the level  
of serum IgA1 O-galactosylation of the Indian sub-group was compared to that of  
the non-Indian IgAN sub-group.  There was no statistically significant difference  
between the level of IgA1 O-hypogalactosylation in the Indian and non-Indian  
IgAN sub-groups (fig. 6).     
 
Further studies should include a larger cohort with a greater representation of the 
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various ethnic groups in order to make valid conclusions regarding the relationship  
between race and IgA1 O-galactosylation in IgAN. 
 
4.2.2 Incidence Data for Black and Indian IgAN Patients in  
         KwaZulu Natal 
 
Seedat et al conducted an analysis of the primary glomerular diseases in 252 Black  
and 75 Indian patients that presented to the Renal Unit at the King Edward VIII 
Hospital, over a period of 6 years i.e. 1981 to 1986 (1988).  This unit was the only  
specialised unit investigating renal diseases in African and Indian patients in Natal,  
the former KZN.  The six year time period matches that of the recruitment period  
of the current study (2006 to 2011).  It is noteworthy that the study by Seedat et al  
revealed a similar race and gender distribution to this study: 2 Africans and 10  
Indians, versus 2 Africans and 11 Indians in this study; with a preponderance of  
males.  However, incidence data should be interpreted with caution as various  
factors, including access to health care, may determine the number of individuals  
that present for diagnosis; and various factors preclude biopsy and hence diagnosis  





4.2.3 IgA1 O-Galactosylation Data for Indian IgAN Patients 
 
Studies from North America (in Caucasian populations and a few in African  
Americans), Europe (in Caucasian populations) and Asia (in Chinese and  
Japanese populations) have demonstrated elevated serum levels of  
hypogalactosylated IgA1 in IgAN patients (Hastings et al, 2010; Shimozato et al,  
2008; Lau et al, 2007;  Moldoveanu et al, 2007; Renfrow et al, 2005; Amore et al,  
2001; Allen et al, 2001; Hiki et al, 2001; Allen & Feehally, 2000; Allen et al, 1999;   
Hiki et al, 1999; Hiki et al, 1998; Tomana et al, 1997; Hiki et al, 1996; Allen et al,  
1995; Tomana et al, 1995; Mestecky et al, 1993).  
 
Following a review of the literature to date (June, 2013), using PubMed and  
Science Direct databases, and the Google search engine, such O-galactosylation  
studies of serum IgA1 in IgAN patients of Indian descent were not found.  In  
addition, studies on the pathogenesis of IgAN in India are limited (Minz et al,  
2010).  The current study provides IgA1 O-galactosylation data for Indian IgAN  
patients.  The study demonstrates that abnormal IgA1 O-galactosylation exists in  
IgAN patients of Indian descent.  Such a finding thus contributes to the  
understanding of the disease pathogenesis in individuals of Indian descent.  Since  
the pathogenesis of IgAN is incompletely understood, it is not known whether  
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causal or pathogenic factors vary between race groups.  It is thus essential for IgA1  
glycosylation studies to be conducted in various race groups in order to elucidate  
the pathogenic mechanisms involved, and to establish if such mechanisms are race- 
specific.  Furthermore, the role of environmental factors and the effect thereof on  
the IgAN pathogenesis is not completely understood; thus studies in different  
populations are required globally. 
 
4.3 IgA1 O-Galactosylation and Gender in IgAN 
 
4.3.1 Sample Size 
 
In the study population, there was no statistically significant difference between  
the level of serum IgA1 O-hypogalactosylation in male and female IgAN patients.   
However, it is noteworthy that the number of male and female participants in this  
study population are too low for statistical comparison (12 males versus 7 females).   
Further studies should include a larger cohort in order to assess for a statistically  





4.3.2 IgA1 O-Galactosylation in Male IgAN Patients 
 
The IgAN study population was predominantly male.  Indeed, IgAN is more  
common in males than females with a 2:1 ratio, and males are associated with a  
worse prognosis than females (Neugarten et al, 2000; Ibels & Gyory, 1994).   
 
For each IgAN participant, the average of each absorbance value (corresponding to  
the level of IgA1 O-hypogalactosylation) from each experiment was obtained.   
When the average of these absorbance values for the male and female IgAN  
patients were compared, the level of serum IgA1 O-hypogalactosylation was higher  
in males than females (fig. 7).  Linossier et al reported that the statistically  
significantly reduced terminal O-galactosylation of serum IgA1 was predominant in  
male IgAN patients (2003).  The gene encoding Cosmc is located on the X- 
chromosome i.e. Xq23 (Ju & Cummings, 2002).  Since males contain a single X- 
chromosome, there may be potential for dominance of any mutation in the gene  
encoding Cosmc, thus predisposing males to abnormal IgA1 O-galactosylation  






4.4 IgA1 O-Galactosylation in Pre-dialysis Versus End-stage  
      IgAN Patients 
 
4.4.1 Sample Size 
 
In the IgAN study population, there was no statistically significant difference  
between the level of IgA1 O-hypogalactosylation in pre-dialysis and end-stage  
IgAN patients.  However, it is noteworthy that the number of pre-dialysis and 
end-stage IgAN patients is too low for a statistically valid comparison (10 end- 
stage versus 9 pre-dialysis IgAN patients).  Further studies should include a larger  
cohort with a greater representation of pre-dialysis and end-stage IgAN patients, in  
order to assess for a statistically significant difference in the IgA1 O- 
hypogalactosylation between such groups.   
 
4.4.2 IgA1 O-Galactosylation and IgAN Progression 
 
For each IgAN participant, the average of each absorbance value (corresponding to  
the level of IgA1 O-hypogalactosylation) was obtained for each experiment.   
When the average of these absorbance values for the end-stage and pre-dialysis  
110 
 
IgAN patients were compared, the level of serum IgA1 O-hypogalactosylation was  
higher in the end-stage patients (fig. 9).  IgA1 O-hypogalactosylation may result in  
prevention of IgA1 clearance from the serum and the generation of galactose- 
deficient IgA1-specific antibodies.  A greater degree of IgA1 O-galactose- 
deficiency may result in enhanced glomerular pathology and thus disease  
progression due to the enhanced induction of galactose-deficient IgA1-specific  
mediated effects viz. complement activation (Hashimoto et al, 2012; Couser, 1985),  
mesangial cell proliferation (Novak, et al 2011), macrophage migration inhibitory  
factor and renin up-regulation (Lai & Leung, 2002), increased apoptosis rate and  
nitric oxide synthesis (Amore et al, 2001), platelet-activating factor induction  
(Coppo et al, 2010), and down-regulation of adiponectin (Inoue, 2012).   
 
Berthoux et al have demonstrated that autoantibodies targeting hypogalactosylated  
IgA1 are associated with the progression of IgAN (2012).  Serum IgG autoantibody  
levels predicted dialysis or death.  In patients with worse clinical outcomes, the  
levels were higher in a stepwise pattern.  In patients with IgAN, the mean serum  
levels of total autoantigen, normalised IgG autoantibody, and total IgA  
autoantibody were significantly higher than in the combined controls (Berthoux et  




4.4.3 Race and IgAN Progression  
 
Although the incidence of IgAN in India is low, the severity is markedly greater  
than that of other populations globally (Chacko, 2011).  The reasons for this  
difference are unknown and Chacko argues that more basic studies and multi-centre  
clinical trials are needed to address this pattern (2011).   In this study, the  
percentage of Indian IgAN patients were higher in both the end-stage (60%) and  
pre-dialysis (67%) sub-groups.  It is noteworthy that the number of patients in the  
end-stage and pre-dialysis IgAN sub-groups are too low to describe associations  
between race and disease progression. 
 
Indeed, Barbour et al reported an increased risk of ESRD in a longitudinal  
observational study of a cohort of 202 individuals of self-reported Pacific Asian  
origin, in comparison to a non-Pacific Asian cohort of 467 individuals.  The non- 
Pacific Asian cohort comprised of 360 Caucasian, 24 Black and 83 individuals  
classified as “Other” (2013).   
 
Individuals of Pacific Asian origin had a significantly increased rate of estimated  
glomerular filtration rate decline with an absolute difference of 1.62  
ml/min/1.73m
2
/year and an increased risk of a 50% reduction in estimated  
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glomerular filtration rate.  
 
4.4.4 Gender and IgAN Progression  
 
The end-stage IgAN group was predominantly male (8 (80%)).  Indeed, the number  
of end-stage and pre-dialysis IgAN patients is too low to describe associations  
between gender and IgAN disease progression.  In a meta-analysis, male IgAN  
patients were significantly associated with a rapid rate of disease progression in  
comparison to female IgAN patients (Neugarten et al, 2000).   
 
4.5 IgA1 O-Galactosylation and Age in IgAN Patients 
 
In the study, no correlation was found between age and IgA1 O- 
hypogalactosylation in IgAN patients.  A meaningful measure of a correlation of  
IgA1 O-hypogalactosylation and age should be a comparison thereof within an  
individual across time.  Such data may also reveal the effect of hypogalactosylation  
on disease progression and provide a comparison for hypogalactosylation within  
periods of remission.   
 
Following a review of the literature to date (June, 2013), using PubMed and  
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Science Direct databases, and the Google search engine, no studies on the effect of  
age on the O-galactosylation of IgA1 in IgAN were conducted. 
 
4.6 IgA1 Concentration and Galactose-Deficiency Per IgA1  
      Molecule 
 
In the study, the IgA1 concentration per serum sample was not measured and the   
IgA1 concentration was thus not standardised for each sample.  Therefore, based on  
a principle of ELISA i.e. the saturation of specific binding points for a concentrated  
test sample, each absorbance value may possibly be an underestimation of the  
galactose-deficiency per IgA1 molecule.   
 
Further studies merit investigation of the galactose-deficiency per IgA1 molecule in  
the study population.  It is essential to assess the level of hypogalactosylation per  
IgA1 molecule in relation to IgAN disease progression; and to compare the extent  
of deficiency among race groups, across gender, and within the same individual  
over time.  Such data may be compared between IgAN populations globally; and  




4.7 Screening and Prognostic Potential of the Lectin        
      Binding Assay for IgAN 
 
Okazaki et al sought to examine the impact of the duration between disease onset 
and first nephrologist consultation on renal prognosis in a retrospective study in 
a Japanese IgAN cohort whose medical records were available for a 10 year 
period (2011).  
 
The rate of increase in serum creatinine levels over the 10 year follow-up period 
was used as a prognostic indicator.  IgAN patients were categorised into 
histological prognostic stages according to the “Clinical guidelines for IgA 
Nephropathy in Japan, 2nd version” (Tomino & Sakai, 2003).  Group 1, 2, 3 and 
4 referred to patients with good prognosis, relatively good prognosis, relatively 
poor prognosis, and poor prognosis respectively.  
 
Okazaki et al reported a significant positive correlation between the duration 
from disease onset to the first medical intervention i.e. a nephrologist 
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consultation and renal prognosis in group 3 patients i.e. patients with relatively 
poor prognosis (2011).  Thus early medical intervention may result in improved 
renal prognosis.  Early screening is required for the subsequent diagnosis via 
renal biopsy in order to provide early medical attention.  
 
The global standardisation of a lectin binding assay for the specific measurement 
of IgA1 O-hypogalactosylation per sample of a specific IgA1 concentration may 
hold promise for a screening or prognostic test for IgAN.  Future studies based 
on global comparative analyses of standardised assay results may serve to 
ascertain a pathogenic level of IgA1 O-hypogalactosylation in IgAN.  Such a 
level may serve as a possible prognostic indicator or a means of screening for 
IgAN.  The lectin-binding assay is relatively rapid and inexpensive in 
comparison to other assays for IgA1 O-galactosylation analysis.  Therefore more 







4.8 Mechanisms Responsible for Abnormal IgA1 O- 
      Galactosylation   
 
This study provides evidence for a pathogenic mechanism of abnormal IgA1 O-  
galactosylation in a population of IgAN patients in South Africa.  For the  
development of specific therapies, further studies need to assess the precise  
mechanism or mechanisms responsible for abnormal IgA1 O-galactosylation in  
such a population.  IgAN is very likely the result of an interplay of multiple factors  
and or mechanisms.   
 
Boyd et al argue that the lack of a clear understanding of the origins of galactose- 
deficient IgA1 and an incomplete understanding of immune complex formation  
have hampered the development of specific therapeutic strategies for the prevention  








4.8.1 Evaluated Hypotheses for Abnormal IgA1 O-Glycosylation 
 
4.8.1.1 Altered Amino Acid Sequence of the IgA1 Hinge Region 
 
It has been hypothesised that a change in the amino acid sequence of the α 1 gene  
encoding the IgA1 hinge region, could alter the template available for O- 
glycosylation.  Greer et al however, reported that the hinge region nucleotide  
sequence was identical in IgAN patients and controls (1998).  Furthermore, Hiki et  
al demonstrated via mass spectrometry that the isolated deglycosylated IgA1 hinge  
region peptide is of identical molecular mass in IgAN patients and controls (1998).   
Such data dispute an abnormality of the hinge-region amino acid sequence and  
provide evidence that the O-glycosylation defect is post-translational. 
 
4.8.1.2 Removal of Terminal Galactose via Glycosidases 
 
It has been hypothesised that the reduced terminal galactosylation of GalNAc could  
be due to its removal by abnormal glycosidase activity in circulation.  However, C1  
inhibitor, one of the few serum proteins with O-glycosylation, does not display the  
same lectin binding pattern as IgA1 from IgAN patients (Allen et al, 1995).  The  
difference in VV binding to C1 inhibitor and IgA1 from patients with IgAN  
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disputes a widespread glycosidase defect.  Such data indicate that abnormal IgA1  
O-glycosylation is a synthetic defect rather than a degradative one. 
 
4.8.1.3 Galactose Addition Defect – β 1,3 GT Functionality  
 
A defect in the addition of galactose to GalNAc may be responsible for abnormal  
IgA1 O-glycosylation in IgAN patients (Allen et al, 1997).   Allen et al compared  
the functional activity of β 1,3 GT, the enzyme responsible for the galactosylation  
of O-linked glycans, in cell lysates of IgAN patients and healthy controls (1997).   
Regalactosylation of degalactosylated IgA1 hinge region fragments from healthy  
controls was measured following incubation with T-cell, B-cell and monocyte  
lysates from IgAN patients and controls.  Hypogalactosylation of the IgA1 hinge  
region was detected following incubation with B-cell lysates from patients with  
IgAN.  Such data demonstrate that a defect in the activity of β 1,3 GT is  







4.8.2 Functionality of Cosmc and β 1,3 GT is Essential for Normal   
         Galactosylation of IgA1 
 
The activity of β 1,3 GT is dependent on the activity of Cosmc which functions as a  
molecular chaperone (Ju and Cummings, 2002).  Aryal et al demonstrated partial  
activity restoration in vitro of denatured β 1,3 GT using Soluble N-terminal 6×His- 
tagged Cosmc (2010).  Aryal et al argue that it is unclear whether the molecular  
chaperone Cosmc requires co-chaperones in vivo (2010). 
 
In a Chinese cohort of IgAN patients, down regulation of Cosmc due to external  
suppression was reported; whilst no genetic mutations for Cosmc were detected  
(Qin et al, 2007).  Similarly, in a European cohort of IgAN patients, no mutations  
in the gene encoding Cosmc were detected; the study did not assess for mRNA  
levels (Malycha et al, 2008). 
 
A deficiency in Cosmc and or β 1,3 GT may be responsible for the abnormal IgA1  
O-galactosylation in the South African IgAN study population.  The specific  
deficiency or deficiencies contributing to abnormal IgA1 O-galactosylation may  
vary in different populations globally and may be influenced by various genetic and  
or environmental factors.  Thus, further studies are required to assess the  
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functionality of Cosmc and β 1,3 GT and factors which may influence the  
functionality thereof in the South African study population of IgAN patients. 
 
 4.8.3 Factors that may Influence Cosmc or β 1,3 GT Functionality  
 
4.8.3.1 Interleukin 4 
 
Yamada et al demonstrated that the Th2 cytokine IL- 4 down-regulates mRNA  
expression of both β 1,3 GT and Cosmc in the human IgA1-positive B-cell line  
(2010).  Stimulation of B-cells with IL-4 also resulted in proliferation of the B- 
cell line, increased IgA1 production and hypogalactosylation of the IgA1 hinge  
region.  The precise mechanism whereby IL-4 influences hypogalactosylation is  
unknown and merits further study.   
 
Although IL-2 increased IgA1 secretion, there was no effect on cell proliferation or  
glycosylation.  Whilst IL-5 stimulated significant cell proliferation, there was little  
or no effect on IgA1 secretion or glycosylation.  Yamada et al thus argue that  
increased cell proliferation and the rate of IgA1 synthesis may not be critical  




Blood mononuclear cells from patients with IgAN produce more IL-4 upon  
mitogen stimulation; express higher levels of mRNA encoding IL-4 and  
demonstrate increased IL-5 activity compared to normal controls (Scivittaro et al,  
1994; Lai et al, 1991).  Compared to patients with mild disease, patients with  
severe renal dysfunction are more likely to hyperproduce IL-4, although they have  
normal IL-4 responses during remission (Lai et al, 1994; Scivittaro et al, 1994; Lai  
et al, 1991).   
 
The levels of IL-4 in the South African IgAN study population have not been  
assessed; further studies are required to assess the levels thereof and to establish if  
hyper-production of IL-4 may be a contributory pathogenic mechanism in the study  
population.  A possible mechanism whereby IL-4 could alter IgA1 O- 
galactosylation may include an abnormally increased IgA1 production per B-cell  
versus cellular proliferation.  Renz et al demonstrated a reciprocal regulatory effect  
of IL-4 on cell growth and immunoglobulin production in human B-cell lines  
(1992).  Such an increase in IgA1 production per B-cell in relation to B-cell  
proliferation, may increase the available IgA1 for galactosylation in relation to the  
level of Cosmc and β 1,3 GT and thus result in pathogenic hypogalactosylated  
IgA1.  The hypothesis of an increase in hypogalactosylation via the mechanism of  
increased IgA1 production per B-cell, differs from the pathogenic mechanism of  
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increased IgA production in IgA myeloma wherein the mechanism responsible for  
increased levels of IgA is clonal expansion of myeloma cells.  It is essential to  
assess the level of IgA1 production per B-cell versus B-cell proliferation in patients  
with IgAN.  Such an investigation was not conducted in the South African IgAN  
study population or in IgAN populations globally; and merits further study in such  
populations.  
 
4.8.3.2 Hypermethylation  
 
A recent study revealed a mechanism of epigenetic silencing of Cosmc in the Tn4  
cell line i.e. immortalised B-cells from a male patient with a Tn-syndrome-like  
phenotype (Mi et al, 2012).  These cells lack transcripts for Cosmc due to  
epigenetic silencing by abnormal hypermethylation of the promoter for the Cosmc  
gene.  The gene encoding Cosmc is located on chromosome Xq24 (Ju and  
Cummings, 2002).  The Tn4 cells also lack β 1,3 GT activity and express the Tn  
antigen.  Treatment of the Tn4 cells with a deoxyribonucleic acid (DNA)  
methylation inhibitor 5-aza-2’-deoxycytidine restored the transcription of Cosmc  
and β 1,3 GT activity.   
 
Qin et al recently reported significantly lower levels of Cosmc mRNA in cultured  
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peripheral B-lymphocytes from IgAN patients, compared to that of normal controls  
(2011).  The level of Cosmc mRNA however, increased significantly upon  
demethylation.  Epigenetic hypermethylation may thus play a role in the  
hypogalactosylation of IgA1 in IgAN patients in which levels of Cosmc expression  
is low. 
 
In mammals, epigenetic mechanisms regulate gene expression, cellular  
differentiation and development, chromosomal integrity preservation, parental  
imprinting, and X-chromosome inactivation (Hermann et al, 2004).  Methylation of  
DNA is carried out by DNA methyltransferases (DNMTs).   
 
In further studies, the state of methylation of the Cosmc promoter should be  
investigated in different populations of IgAN cohorts in which Cosmc expression is  
low.    
 
The level of Cosmc expression in the study population or any South African IgAN  
population has not been investigated; nor has the effect of demethylation on Cosmc  
expression been examined; further studies are required for the investigation thereof.  
If such a mechanism of abnormal hypermethylation of the Cosmc promoter in  
IgAN is established, then further studies to elucidate the mechanisms responsible  
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for hypermethylation should be conducted.  Such pathogenic mechanisms that may  
be responsible for hypermethylation include the upregulation of DNMTs; loss of  
protection of the promoter by DNA binding proteins or transcription factors (Mi et  
al, 2012); loss of protection due to hypermethylation of the Alu elements that  
surround the promoter; or the recognition of the methylated promoter by methyl- 
CpG (cytosine-phosphate-guanine)-binding domain proteins that recruit the histone  
deacetylase-containing transcription repression complex which stops Cosmc  
transcription (Bogdanovic & Veenstra, 2009; Patra & Bettuzzi, 2009). 
 
In addition, investigations into possible mutations in the gene encoding Cosmc  
in the South African study IgAN population or any South African IgAN population  
have not been conducted; further studies are required for the establishment thereof.   
Inactive Cosmc may result in inactivity of β 1,3 GT and hence abnormal IgA1 O- 
galactosylation. 
 
4.8.3.3 MicroRNA (miR) - 148b 
 
Serino et al recently identified a new regulatory factor for the expression of β1,3  
GT, and hence the levels of IgA1 O-galactosylation, in peripheral blood  
mononuclear cells (PBMCs) of IgAN patients (2012).  High throughput miRNA 
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profiling revealed a significant up-regulation of miR-148b in the PBMCs  
of IgAN patients in comparison to healthy controls and patients with other renal  
diseases i.e. 3 membranoproliferative glomerulonephritis type I patients, 5 focal  
segmental glomerulosclerosis patients, and 10 HSP-nephritis patients. 
 
The β 1,3 GT expression was significantly lower in IgAN patients in comparison to  
healthy controls and there was a significant negative correlation between β 1,3 GT  
mRNA levels and miR-148b expression levels.   
 
Endogenous β 1,3 GT mRNA levels were significantly reduced by 3-fold in  
PBMCs from healthy controls following transfection with a miR-148b mimic.   
Transfection of PBMCs from the IgAN patients with a miR-148b inhibitor led to a  
significant 3-fold endogenous increase in β 1,3 GT mRNA levels.   
 
The level of IgA1 O-hypogalactosylation was significantly higher in IgAN patients  
than controls and was significantly positively correlated with the miR-148b  
expression level; thus supporting the role of miR-148b as a down-regulator of β1,3  
GT.  To support the role of up-regulated miR-148b in the hypogalactosylation of  
IgA1, IgA1-producing human B lymphoma cells were transfected with the miR- 
148b mimic and inhibitors.  Transfection with the miR-148b mimic led to   
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a significant increase in hypogalactosylated IgA1whilst transfection with the miR- 
148b inhibitor led to a significant decrease in hypogalactosylated IgA1.     
 
Serino et al argue that the manipulation of miR-148b levels may provide a potential  
therapeutic strategy in IgAN (2012).   
 
The expression of β 1,3 GT was not investigated in the study population or any  
South African IgAN population.  In order to elucidate the mechanisms responsible  
for the abnormal IgA1 O-galactosylation demonstrated in the study population, it is  
essential to investigate the levels of expressed β 1,3 GT.  A deficiency thereof may  
warrant further investigation into miR-148b levels.  It is also essential to assess for  
possible mutations in the gene encoding β 1,3 GT; it may be possible that inactivity  
of β 1,3 GT due to genetic mutation may be responsible for the abnormal IgA1 O- 
galactosylation demonstrated in the South African IgAN study population. 
 
4.9 Proposed Therapeutic Strategy for an IgAN Population  
      with Hypogalactosylated IgA1 
 
Kobayashi et al reported a reduction in serum IgA levels and an increase in the  
sialylation and galactosylation thereof in ddY mice following IL‐12 administration  
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(2002).  IL-12 induces a shift from the Th2 to Th1 response, which may have  
resulted in the reduction of Th2 cytokine levels such as IL‐4 and IL‐5, resulting in  
increased sialylation and galactosylation of IgA.  Kobayashi et al argue that such  
data confirm a down-regulation of the clonal expansion of IgA-producing B-cells  
and thus a reduced level of IgA1 (2002).  
 
However, Kobayashi et al reported a slight but not significant worsening of renal  
function and crescent formation following IL-12 administration (2002).  Kobayashi  
et al argue that although the duration of the study was too short to make  
conclusions about a detrimental impact of IL-12 administration on glomerular  
pathology, further up‐regulation of TGF‐β due to prolonged IL‐12 administration  
may accelerate nephrosclerosis (2002). 
 
Thus, following review of the literature, it can be newly hypothesised that  
monoclonal antibody therapy against IL-4 may serve as a possible therapeutic  
approach in patients with IgAN; as opposed to the possible use of recombinant  
IL-12 therapy which although may create a shift away from the Th2 response, may  
also result in nephrosclerosis due to the cell-mediated Th1 response.  In the  
South African IgAN study population the levels of IL-12 in addition to IL-4 were  
not studied; investigation thereof may provide significant information regarding the  
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pathology of IgAN in the study population with abnormal hypogalactosylated  
IgA1. 
 
4.10 Proposed Therapeutic Strategies for the Amelioration of  
        Renal Mesangium Pathology in an IgAN Population   
        with Hypogalactosylated IgA1 
 
Based on the pathogenic effects of galactose-deficient IgA1 on the renal  
mesangium, potential therapeutic strategies for the amelioration thereof, may  
include the following in mesangial cells: down-regulation of renin and macrophage  
migration inhibitory factor (refer to 1.3.6.8.1); up-regulation of adiponectin  
secretion in mesangial cells (refer to 1.3.6.8.2); and suppression of platelet- 
activating factor (refer to 1.3.6.8.5). 
 
4.11 Mycophenolic Acid and Up-regulation of Cosmc 
 
A recent study demonstrated that mycophenolic acid, an immunosuppressant used  
to prevent allograft rejection, can up-regulate the expression of Cosmc in B- 
lymphocytes of IgAN patients in vitro and increase the IgA1 O-galactosylation  
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level (Xie et al, 2013).  
 
Mycophenolic acid induces a cytostatic effect in lymphocytes (Allison & Euqui,  
1996).   
 
The precise mechanism whereby mycophenolic acid may result in the up-regulation  
of Cosmc is unknown. 
 
Currently, evidence supporting the use of mycophenolic acid in treating IgAN is  
inconclusive.  Trials to date are of small size, and longer term studies are required  
(Tang et al, 2010). 
 




4.12.1.1 The study addresses the paucity of data on the pathogenesis of IgAN from   
              Africa. 
 
4.12.1.2 IgAN is a disorder for which the pathogenetic mechanisms are not fully  
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              understood worldwide.  The study provides evidence for a pathogenetic  
              mechanism of abnormal IgA1 O-galactosylation in IgAN patients from  
              KwaZulu Natal, South Africa.  The study is thus an essential contribution  
              towards the understanding of the disease pathogenesis. 
 
4.12.1.3 Since the study was based on an initiating event in the pathogenesis of  
              IgAN, i.e. the hypogalactosylation of IgA1, such data may inform the  
              research into specific therapies for IgAN which currently do not exist.  
 
4.12.1.4 Since abnormal IgA1 O-glycosylation was demonstrated to be a  
              pathogenic mechanism in the IgAN study population, the study data may   
              lend support to the potential usefulness of specific therapies targeting the  
              pathogenetic mechanism of aberrant IgA1 O-galactosylation in the study   
              population of IgAN patients from KwaZulu Natal South, Africa. 
 
4.12.1.5 The study was based on broad inclusion criteria.  The lack of homogeneity  
              in the study group due to the inclusion of various race groups, a wide age  
              distribution, both genders, and both pre-dialysis and end-stage IgAN  
              patients, precludes restrictive applicability of the study data to a select  
              patient sub-group.  
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4.12.1.6 The utilisation of a relatively rapid and inexpensive assay for the  
              investigation of the IgA1 O-galactosylation i.e. the Vicia villosa lectin-       
              binding assay, enables the production of comparable pathogenetic data in   
              other resource-restricted countries, particularly in Africa.  
 
4.12.1.7 The study highlights the potential future utility of the lectin binding assay  
              for the determination of abnormal IgA1 O-galactosylation as a future  
              screening tool for IgAN. 
 
4.12.1.8 The study provides IgA1 O-glycosylation data for IgAN patients of Indian  
              ethnicity.  Following review of the literature to date, IgA1 O-glycosylation  
              data does not exist for IgAN patients of Indian ethnicity.   
 
4.12.1.9 The study highlights a new hypothetical therapeutic strategy targeting  
              abnormal IgA1 O-galactosylation, which merits investigation, i.e.  
              monoclonal antibody therapy against IL-4.   
 
4.12.1.10 The study highlights avenues for further study for the elucidation of the   
                mechanisms responsible for abnormal IgA1 O-galactosylation in the  
                study population. 
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4.12.1.11 The study highlights therapeutic strategies that target the amelioration of  




4.12.2.1 The number of patients diagnosed with IgAN at the IALCH i.e. the  
              hospital from which IgAN patients were recruited, and the lack of consent  
              to the study by some IgAN patients dictated the sample size and sub-group  
              demographics; and hence, precluded sub-group IgA1 O-galactosylation  
              analyses. 
 
              Thus, the IgA1 O-galactosylation analyses between racial groups, between  
              genders, and between pre-dialysis and terminal IgAN patients were  
              precluded by a low IgAN patient sub-group sample size.  
 
4.12.2.2 The level of IgA1 O-hypogalactosylation per IgA1 molecule and the level  
              of IgA1 per sample was not standardised; however this does not influence  







Prior to this study, the O-glycosylation state of IgA1 in South African IgAN  
patients had not been defined.  This study provides pathogenetic data on IgAN,  
which is scarce or nil in African countries to date.  The data of this study is thus an  
essential contribution towards the global advancement in the understanding of the  
pathogenesis of IgAN and the eventual development of specific therapies.   
 
In this study, the hypothesis of abnormal serum IgA1 O-galactosylation in IgAN  
patients was proven.  Thus, specific therapies developed against the pathogenic  
mechanism of IgA1 O-hypogalactosylation may potentially be of benefit in this  
study population.   
 
Further studies are required to elucidate the specific mechanisms responsible for  
abnormal IgA1 O-galactosylation in the South African population.  Based on the  
data of this study, further investigation into the levels of Cosmc and β 1,3 GT, and  
possible genetic mutations thereof are required in the IgAN study population.   
Serum IL-4 levels merits investigation in the study population.  The mechanisms  
whereby IL-4 may decrease galactosylation of IgA1 in patients with IgAN is  
currently unknown; investigation into the mechanisms thereof should  
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be conducted in IgAN populations globally.  Increased IgA1 production per B-cell  
in relation to B-cell proliferation, due to possible enhanced IL-4 levels is  
hypothesised as a possible mechanism responsible for abnormal IgA1 O- 
galactosylation in IgAN.  
 
It is further hypothesised that monoclonal antibody therapy against IL-4 may serve  
as a potential therapeutic agent for IgAN.  The effect of monoclonal antibody  
therapy against IL-4 on IgA1 O-galactosyltion in cultured B-lymphocytes from  
patients with IgAN merits further study in the study population and in other IgAN  
populations globally. 
 
IgAN is a multifactorial disease and is “not the same disease” (Feehally, 2010;  
personal communication) in all parts of the world (differing prognoses and  
presentation), but this finding of abnormal IgA1 O-galactosylation is consistent  
with that of other populations globally; and thus supports universal strategies for  
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Asialoglycoprotein receptor (ASGPR) 
core 1 β3-galactosyltransferase (β 1,3 GT) 
Complement (C) 
Complementarity determining region (CDR) 
Constant Heavy (CH) 
Constant Light (CL) 
Council for Scientific and Industrial Research (CSIR) 
Cysteine (Cys) 
Deoxyribonucleic acid (DNA) 
DNA methyltransferases (DNMTs) 
End-stage renal disease (ESRD) 
Enzyme-linked immunosorbent assay (ELISA) 
Ethylenediaminotetraacetic acid (EDTA) 
Fetal calf serum (FCS) 
Figure (fig.) 
Fish oil supplements (FOS) 
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Fluorophore-assisted carbohydrate electrophoresis (FACE) 
Fragment antigen binding (Fab) 
Fragment crystallisable (Fc) 
Grouped ddY (gddY) 
Helix aspersa (HA) 
Henoch-Schönlein Purpura (HSP) 
High performance liquid chromatography (HPLC) 
High serum IgA (HIGA) 
Horse radish peroxidase (HRP) 
Immunoglobulin A1 (IgA1) 
Immunoglobulin A Nephropathy (IgAN) 
Inkosi Albert Luthuli Central Hospital (IALCH) 
Interleukin (IL) 
International Society of Nephrology (ISN) 
KwaZulu Natal (KZN) 
Macrophage galactose-type lectin (MGL) 
Mannose-binding lectin (MBL) 
Matrix assisted laser desorption ionising mass spectroscopy (MALDI-MS) 






N-Acetylneuraminic acid (NeuNAc) 
Nelson R. Mandela School of Medicine (NRMSM) 
Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) 
Number (no.)  
Not applicable (N/A) 
o-Phenylenediamine (OPD) 
Peripheral blood mononuclear cells (PBMCs) 
Phosphate-buffered saline (PBS) 
Revolutions per minute (rpm) 
Serine (Ser) 
Standard Error of the Mean (SEM) 
Threonine (Thr) 
Transforming growth factor ß (TGF-ß) 
United States of America (USA) 
University of KwaZulu Natal (UKZN) 
Variable Heavy (VH) 
Variable Light (VL) 













       
       
       





















2009 - 6 May CAM37 37 African Male 
2008 - 18 Aug CAF24273 35 African Male 
2009 - 1 Oct CAF42 42  African  Female 
2008 - 18 Aug CAF24289 25 African Female 
2008 - 18 Aug CAF24282 35 African  Female 
2008 - 18 Aug CAF24262 36 African Female 
2009 - 22 May CCF40 40 Caucasian Female 
2009 - 6 May CCF27 27 Caucasian Female 
2009 - 6 May CCF24 24 Caucasian Female 
2008 - 18 Aug CCLF24284 23 Coloured Female 
2009 - 22 May CIM11 40 Indian Male 
2009 - 12 May CIM33 33 Indian Male 
2009 - 12 May CIM21 21 Indian Male 
2008 - 18 Aug CIM24250 49 Indian Male 
2008 - 18 Aug CIM24261 30 Indian Male 
2008 - 18 Aug CIM24288 25 Indian Male 
2008 - 18 Aug CIM24281 25 Indian Male 
2009 - 22 May CIF35 35 Indian  Female 
2008 - 18 Aug CIF24283 21 Indian  Female 























 Indian African Caucasian Coloured 
Number of Controls 10 6 3 1 
Proportion of Controls (%) 50 30 15 5 
Proportion Male (%)  70 33.3 0 0 
Mean Age  37 35 30 N/A 
Age range 19-49 25-42 24-40 23 
Median Age 28 35 27 N/A 
Female Mean Age 25 35 30 N/A 
Female Median Age 21 36 27 N/A 
Male Mean Age 33 36 N/A N/A 
Male Median Age 30 36 N/A N/A 
Age Range Female 19-35 25-42 N/A N/A 




Table 3:  Experimental and Control Population: Age Range and Age, Race, 











 Experimental Population Control Population 
Age Range 29-66: 29, 31, 35, 37, 37, 38, 
40, 40, 43, 43, 45, 46, 48, 
51, 51, 54, 59, 63, 66 
 
19-49: 19, 21, 21, 23, 24, 
25, 25, 25, 27, 30, 33, 35, 
35, 35, 36, 37, 40, 40, 42, 49 
Median Age 43 32 
Mean Age 46 31 
Mean Age Male 44 33 
Mean Age Female 41 30 




Table 4:  Experimental Population Encoding and Descriptors  
 
Extraction Date Code Age 
(Years) 
Race Gender End-stage 
IgAN 
2009 - 4 June PAM13072 29 African Male No 
2011- 3 March PAM02011 45 African Male Yes - dialysis 
2009 - 4 June PCM04952 40 Caucasian Male Yes - transplant 
2009 - 4 June PCF02620 40 Caucasian Female Yes - transplant 
2009 - 26 March PCLM08931 54 Coloured  Male Yes - transplant 
2009 - 26 March PCLM03297 37 Coloured  Male No 
2007 - 28 June PCLF2024 46 Coloured  Female No 
2009 - 3 September PIF5300 59 Indian/Caucasian Female No 
2007 - 12 July PIM8434 43 Indian Male No 
2007 - 19 July PIM1829 48 Indian Male Yes - transplant 
2009 - 2 June PIM2407 63 Indian Male Yes - transplant 
2009 - 25 August PIM2945 51 Indian Male Yes - transplant 
2009 - 2 June PIM1971 38 Indian Male Yes - transplant 
2009 - 2 June PIM26745 35 Indian Male Yes - dialysis 
2009 - 4 June PIM2386 43 Indian  Male No 
2007 - 28 June; 
2009 - 4 June 
PIF03104 64/66 Indian Female No 
2009 - 2 June PIF1274 37 Indian Female No 
















 Indian African Caucasian Coloured Mixed Race 
Indian/Caucasian 
Number of  
Experimental 
Participants 




57.89 10.53 10.53 15.79 5.26 
Proportion Male 
(%)  
70 100 50 66.7 0 
Mean Age  46 37 40 46 N/A 
Age range 31-66 29 & 45 40 & 40 37-54 59 
Median Age 43 N/A N/A 46 N/A 
Female Mean Age 46 N/A N/A N/A N/A 
Female Median Age 43 N/A N/A N/A N/A 
Male Mean Age 46 N/A N/A 46 N/A 
Male Median Age 48 N/A N/A N/A N/A 
Age Range Female 31-66 N/A 40 46 59 




Table 6:  Consumables/Reagents and Manufacturer 
Consumables/Reagents  Manufacturer 
15 ml polypropylene centrifuge tube  Corning; New York, USA 
Cryogenic vials (2.0 ml) Corning; New York, USA 
1.5 ml microcentrifuge tube Eppendorf; Hamburg, Germany 
50 ml polypropylene tube  Sterilin; Newport, United Kingdom 
Costar 96-well plate   Corning; New York, USA 
Polyethylene Wrap Glad; Babelegi, South Africa 
Rabbit Anti-human IgA (1 ml) Dako; Glostrup, Denmark 
Carbonate/bicarbonate buffer capsules Sigma; St. Louis, USA 
PBS tablets Sigma; St. Louis, USA 
NaCl  Sigma-Aldrich; Milwaukee, USA  
Tween 20  Sigma; Steinheim, Germany 
FCS Highveld Biological; Johannesburg, 
South Africa 
Biotinylated VV lectin (2mg) Vector; California, USA 
Horseradish Peroxidase Avidin D 
Concentrate (5 mg) 
Vector; California, USA  
OPD tablets Dako; Glostrup, Denmark 
30% H2O2 solution (500 ml)  Sigma; Steinheim, Germany 


















Average of the Means 
Across the Plates for 5 μl 






















6 50/0 0.1885 
6 25/25 0.085 
6 12.5/37.5 0.0545 
7 50/0 0.5195 
8 50/0 0.948 
10 5/495 0.03025 
12 5/495 0.019 
13 5/495 0.07475 
14 5/495 0.2155 



















7 50/0 1.103 
8 50/0 1.518 
9 5/495 0.1365 
10 5/495 0.07175 
11 5/495 0.06325 
12 5/495 0.175 
13 5/495 0.05925 

















8 50/0 1.2905 
9 5/495 0.0275 
10 5/495 0.01875 
11 5/495 -0.05525 
12 5/495 -0.0535 

















7 50/0 1.0985 
8 50/0 1.9135 
9 5/495 0.11 
10 5/495 0.02675 
11 5/495 0.03525 
12 5/495 -0.042 

















8 50/0 0.854 
9 5/495 0.188 
10 5/495 0.09775 
11 5/495 0.06825 
12 5/495 0.2895 
13 5/495 0.21775 















8 50/0 0.3625 
9 5/495 0.069 
10 5/495 0.04475 
11 5/495 -0.04525 
12 5/495 -0.055 



















8 50/0 1.1895 
9 5/495 0.1225 
10 5/495 0.01575 
11 5/495 0.01225 
12 5/495 -0.034 
13 5/495 0.07075 



















7 50/0 0.5305 
8 50/0 1.3415 
9 5/495 0.254 
10 5/495 0.15675 
11 5/495 0.19925 
12 5/495 0.058 
13 5/495 0.27425 





















6 25/25 0.161 
6 12.5/37.5 0.048 
8 50/0 1.1125 
9 5/495 0.047 
10 5/495 0.03075 
11 5/495 -0.00775 
12 5/495 -0.021 
13 5/495 0.04525 




5 25/25 -0.015 0.074541667 
  
  
8 50/0 1.1955 













11 5/495 -0.00625 
12 5/495 0.002 
13 5/495 0.05975 
14 5/495 0.259 













10 5/495 0.04275 
11 5/495 0.02125 
12 5/495 0.047 
13 5/495 0.06275 















7 50/0 0.864 
8 50/0 1.292 
10 5/495 0.07175 
12 5/495 -0.0595 
13 5/495 0.08725 













9 5/495 0.1225 
10 5/495 0.07275 
11 5/495 0.01225 
12 5/495 -0.042 











7 50/0 0.219 
8 50/0 0.344 
10 5/495 0.06725 





13 5/495 0.11825   










10 5/495 0.05975 
12 5/495 -0.016 


















8 50/0 1.5255 
9 5/495 0.063 
10 5/495 0.05625 
11 5/495 0.04075 
12 5/495 0.8435 
13 5/495 0.11175 

















8 50/0 1.7445 
9 5/495 0.0865 
10 5/495 0.06275 
11 5/495 0.04675 
12 5/495 -0.0665 
13 5/495 0.06225 

















8 50/0 1.201 
9 5/495 0.107 
10 5/495 0.06475 
11 5/495 0.00275 
12 5/495 0.168 
13 5/495 0.09375 








   
  
  








8 50/0 0.303 
9 5/495 0.1185 
10 5/495 0.06225 
11 5/495 0.03525 
12 5/495 0.077 
13 5/495 0.09975 


















Table 8:  Absorbance Data for Each Control Participant 







Average of the 
Means Across 
the Plates 
CAM 37 2 25/25 -0.276 0.0649375 
  4 25/25 0.0045   
  6 50/0 0.1075   
  6 25/25 0.0595   
  6 12.5/37.5 0.0575   
  8 50/0 0.241   
  9 5/495 0.066   
  10 5/495 0.05375   
  11 5/495 0.02725   
  12 5/495 0.0165   
  13 5/495 0.14675   
  14 5/495 0.275   
CAM24273 10 5/495 0.05875 0.05875 
CAF42 1 25/25 0.0132 0.23455 
  4 25/25 0.0045   
  7 50/0 0.591   
  8 50/0 1.1865   
184 
 
  9 5/495 0.0705   
  10 5/495 0.06125   
  11 5/495 0.07425   
  12 5/495 -0.042   
  13 5/495 0.15175   
CAF24289 10 5/495 0.03725 0.1061875 
  11 5/495 0.01275   
  13 5/495 0.10125   
  14 5/495 0.2735   
CAF24282 10 5/495 0.00625 0.00625 
CAF24262 10 5/495 0.06475 0.06475 
CCF40 1 25/25 0.0597 0.172095 
  4 25/25 0.0035   
  7 50/0 0.4945   
  8 50/0 0.7   
  9 5/495 0.0565   
  10 5/495 0.04675   
  11 5/495 -0.01075   
  12 5/495 0.035   
  13 5/495 0.11125   
  14 5/495 0.2245   
CCF27 2 25/25 -0.0305 0.24478125 
185 
 
  8 50/0 1.505   
  9 5/495 0.0625   
  10 5/495 0.05975   
  11 5/495 0.03125   
  12 5/495 -0.027   
  13 5/495 0.10525   
  14 5/495 0.252   
CCF24 3 25/25 0.02975 0.152 
  4 25/25 0.0125   
  7 50/0 0.3945   
  8 50/0 0.5945   
  9 5/495 0.087   
  10 5/495 0.08875   
  11 5/495 0.04925   
  12 5/495 -0.057   
  13 5/495 0.16875   
CCLF24284 9 5/495 0.095 0.0871875 
  10 5/495 0.05125   
  11 5/495 0.05925   
  13 5/495 0.14325   
CIM11 2 25/25 -0.171 0.179027778 
  7 50/0 0.6295   
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  8 50/0 0.689   
  9 5/495 0.056   
  10 5/495 0.06225   
  11 5/495 -0.00075   
  12 5/495 0.02   
  13 5/495 0.09475   
  14 5/495 0.2315   
CIM33 1 25/25 0.0302 0.1765375 
  5 25/25 -0.0315   
  6 50/0 0.211   
  6 25/25 0.1805   
  6 12.5/37.5 0.098   
  8 50/0 0.749   
  9 5/495 0.073   
  10 5/495 0.04625   
  11 5/495 0.02475   
  12 5/495 0.3045   
  13 5/495 0.12125   
  14 5/495 0.3115   
CIM21 3 25/25 0.04175 0.211888889 
  7 50/0 0.174   
  8 50/0 1.2295   
187 
 
  9 5/495 0.056   
  10 5/495 0.04775   
  11 5/495 0.01625   
  12 5/495 0.0145   
  13 5/495 0.10675   
  14 5/495 0.2205   
CIM24250 9 5/495 0.057 0.08255 
  10 5/495 0.02625   
  11 5/495 0.00225   
  13 5/495 0.06925   
  14 5/495 0.258   
CIM24261 10 5/495 0.05725 0.151833333 
  13 5/495 0.13425   
  14 5/495 0.264   
CIM24288 10 5/495 0.05725 0.135833333 
  13 5/495 0.10875   
  14 5/495 0.2415   
 CIM24281 9 5/495 0.1 0.13825 
  10 5/495 0.06625   
  13 5/495 0.11575   
  14 5/495 0.271   





  7 50/0 1.047   
  8 50/0 1.738   
  9 5/495 0.0725   
  10 5/495 0.02925   
  11 5/495 0.03525   
  12 5/495 0.1745   
  13 5/495 0.08825   
  14 5/495 0.0885   
CIF24283 9 5/495 0.034 0.07145 
  10 5/495 0.02975   
  11 5/495 -0.00625   
  13 5/495 0.08725   
  14 5/495 0.2125   
CIF24280 9 5/495 0.0905 0.10335 
  10 5/495 0.03575   
  11 5/495 0.02325   
  13 5/495 0.10975   
  14 5/495 0.2575   
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